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ABSTRACT 
In engineering a cartilage tissue, the survival of the chondrocytes is directly 
interdependent to the extracellular matrix production. Therefore, the choice of 
biomaterials for cartilage tissue engineering application is crucial in determining the 
survival of the chondrocytes. Natural biomaterials pose great advantages for tissue 
engineering applications due to their biocompatibility, biodegradability and ease of 
availability.  These materials are not only sustainable but pose a lower risk of rejection 
by the body. Human Amniotic Membrane (HAM), for example, is a 2 dimensional (2D) 
biocompatible and biodegradable material. The main objective of this study is to 
develop a 3 dimensional (3D) scaffold made from HAM a well-known natural 
biomaterial to supports chondrocytes proliferation and matrix production with an 
ultimate aim to promote tissue regeneration in cartilage tissue engineering application. 
This thesis presents the development of a novel 3D HAM/ Fibrin scaffold that was 
produced from a crosslink of HAM extracts and fibrin to form a stable scaffold to 
ensure uniform cell dispersion throughout the scaffold. This thesis also outlines the 
parameters that validate the feasibility of the scaffold following the success of 
optimization of the developed 3D HAM/ Fibrin scaffold (1:1 (v/v) ratio of HAM/ Fibrin 
with a concentration of 5 million cells/ml set within 30 minutes). The results of total 
DNA and GAG content production of this novel scaffold supports the cartilage matrix 
production and cell survival in vitro. Predominantly, chondrocytes favoured the HAM/ 
Fibrin scaffold as results for both DNA and GAG content recorded a significant 
increase than the control group. Moreover, the histological evaluation also revealed 
chondrocytes favouring HAM/ Fibrin scaffold when it comes to proteoglycans synthesis 
which further supports the result from the DNA and GAG content production. The 
FESEM evaluation also affirms the DNA and GAG content production favouring HAM/ 
Fibrin scaffold with apparent signs of cell-cell connection, cell-ECM adhesion and 
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cytoskeletal filaments. This study is a step forward in scaffold fabrication for cartilage 
tissue engineering as it is a known fact that HAM constituents are quite similar to native 
cartilage and the results from this study further support the use of natural biomaterial in 
mimicking the native microenvironment of the intended tissue replacement. 
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ABSTRAK 
Dalam kejuruteraan tisu tulang rawan, kemandirian sel kondrosit adalah secara langsung 
saling bergantung kepada pengeluaran matriks ekstraselular. Oleh itu, pilihan biobahan 
untuk aplikasi kejuruteraan tisu tulang rawan adalah penting dalam menentukan 
kemandirian sel kondrosit. Biobahan semula jadi memberi kelebihan yang besar untuk 
aplikasi kejuruteraan tisu kerana keupayaan bioserasi, biodegradasi dan mudah 
diperoleh. Bahan-bahan ini bukan sahaja mampan, tetapi menimbulkan risiko penolakan 
yang lebih rendah oleh tubuh badan. Sebagai contoh, Membran Amniotik Manusia 
(HAM) ialah bahan bioserasi dan biodegradasi 2 dimensi (2D). Objektif utama kajian 
ini adalah untuk membangun perancah 3 dimensi (3D) yang diperbuat daripada HAM 
yang merupakan biobahan semula jadi yang terkenal untuk menyokong proliferasi sel 
dan penghasilan matriks dengan matlamat utama untuk mempromosikan pertumbuhan 
semula tisu dalam aplikasi kejuruteraan tisu tulang rawan. Tesis ini membentangkan 
perkembangan perancah 3D HAM/ Fibrin yang dihasilkan daripada sambungan silang 
ekstrak HAM dan fibrin untuk membentuk hidrogel yang stabil dan memastikan 
penyebaran sel yang seragam di seluruh perancah. Tesis ini juga menggariskan 
parameter yang mengesahkan kebolehan perancah berikutan kejayaan pengoptimuman 
perancah 3D HAM/ Fibrin(nisbah 1: 1 (v/v) HAM/ Fibrin dengan kepekatan 5 juta sel/ 
ml yang ditetapkan dalam masa 30 minit masa). Hasil total produksi DNA dan GAG 
kandungan perancah novel ini menyokong produksi matriks rawan dan kemandirian sel 
in vitro. Keseluruhannya, sel kondrosit menggemari perancah HAM/ Fibrin sebagai 
hasil untuk kedua-dua kandungan DNA dan GAG mencatat peningkatan yang ketara 
daripada kumpulan kawalan. Selain itu, penilaian histologi juga mendedahkan sel 
kondrosit yang memihak kepada perancah HAM/ Fibrin apabila ia berkaitan dengan 
sintesis proteoglycans yang seterusnya menyokong hasil daripada pengeluaran jumlah 
kandungan DNA dan GAG. Penilaian FESEM juga mengesahkan pengeluaran jumlah 
vi 
kandungan DNA dan GAG yang memihak kepada perancah HAM/ Fibrin dengan bukti 
kehadiran sambungan sel-sel, lekatan sel-ECM dan filamen sitoskeletal. Kajian ini 
adalah satu langkah ke hadapan dalam fabrikasi perancah untuk kejuruteraan tisu tulang 
rawan kerana ia adalah suatu fakta yang diketahui bahawa komponen membran 
amniotik manusia adalah agak sama dengan tulang rawan asli dan hasil kajian ini 
menyokong lagi penggunaan biobahan semula jadi dalam mencontohi alam mikro asli 
tisu bagi tujuan penggantian tisu. 
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CHAPTER 1: INTRODUCTION 
1.1 Tissue Engineering 
Human life expectancy is better than it was decades ago. The improvements in 
medical science have been contributing to this phenomenon. However, as we grow 
older, so is the need for our body to repair itself as tissue and organ wears-off and aging 
takes effect. Loss of tissues or organs due to pathological or trauma reasons often 
resulting in a need of a tissue or organ transplant for replacement. Although organ 
transplantation and artificial organ may be the best solution, it is not without 
morbidities. The scarce supplies in organ donation and the risk of immune rejection is 
still a conundrum in organ transplantation.  
Remarkable advances in biomedical engineering field have given rise to advances in 
artificial organs, however, it still has issues in relation to biocompatibility and bio-
functionality within in vivo environment. As an alternative, a new approach to tissue 
and organ reconstruction and replacement was introduced in 1993 by growing a human 
ear on the back of a mouse (Langer & Vacanti, 1993). This later was followed by other 
success such as trachea, bones and pulmonary arteries tissues cultured and engineered in 
laboratory through the technology now known as Regenerative Medicine.  
Regenerative medicine can be classified into two categories as depicted in Figure 
1.1. It involves two concepts with either the presence or absence of scaffold(s) to 
support tissue regeneration.  
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Figure 1.1: Classification of Regenerative Medicine based on the use of scaffold. 
Adapted from (Ikada, 2006). 
 
1.2 Concept of Tissue Engineering 
The basic concept of tissue engineering is to regenerate patient’s own tissue and 
organ by using their own cells; be it blood, skin or muscle that would be biocompatible 
and bio-functional with almost zero immune rejection.  It is often considered as an 
ultimate and ideal alternative of medical treatment.  
In regenerating new tissues and organs, tissue engineering utilizes three basic 
ingredients; the cell, three dimensional (3D) scaffolds and growth factor as illustrated in 
Figure 1.2, all of which, interplay in reconstructing and regenerating a functional tissue 
or organ (Langer & Vacanti, 1993).  
Obtaining adequate cells is a major challenge since many of the cell type taken from 
adult source has a very limited capacity for expansion. The presence of cells alone are 
questionable to form tissues. Although direct injectable was often used by using cell 
suspension, it has very little success in regenerating functional tissues. When cells are 
removed from their natural in vivo environment, they often lose their tissue-specific 
function, also known of phenotype. Cells must somehow adhere to a temporary 
structure or also known as scaffold which mimics the 3D environment it was used to for 
which it will adhere and organize into functional tissues. 
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Figure 1.2: Tissue Engineering Triad. Adapted from (Partap, Plunkett, & 
O’Brien, 2010). 
 
 A 3D biomaterial scaffold basically provides a temporary support for cells to grow 
and aid in cellular attachment. Meanwhile, the presence of growth factor cultivates the 
direction of which the cells would grow, proliferates, differentiates, migrates and even 
programmed cell death (apoptosis). Cells interact with soluble growth factors and 
cytokines as well as insoluble factors such as the extracellular matrix (ECM) and other 
cells in the cell-ECM interactions and cell-to-cell interactions. 
The signaling cues to and from the neighboring cells and ECM plays an important 
role in regulating cell function. Cells are interconnected to each other with adhesion 
molecules called integrins which links intracellular to ECM. Most studies on 
engineering cellular microenvironment were performed in two dimensional (2D) while 
cells in the native environment are naturally in 3D organization. Studies have shown 
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that cells cultured in 3D environment present distinct phenotype from the same cells 
cultured in 2D settings (Benya & Shaffer, 1982) 
Among many other strategies in fabricating functional tissue construct, scaffold 
based constructs offer the greatest potential for microenvironment control specifically in 
modifying the presence of bioactive ligands and proteolytic remodeling. The integration 
of these elements is important to fabricate the scaffold that can support the growth and 
maintenance of specific cell phenotype, ultimately the desired functional tissue 
construct. 
1.3 Cartilage Tissue Engineering 
Joint pain is a major cause of disability in middle-aged and older population. 
Damage to the articular cartilage may cause subsequent degeneration that may lead to 
osteoarthritis and other joint diseases. Millions of surgeries were done annually to treat 
this cartilage defects worldwide, caused either by trauma, osteonecrosis or 
osteochondritis. Approximately 70% of population aged 65 years and above are 
currently affected in some way by osteoarthritis (Buckwalter & Mankin, 1998). Until 
now, there is no current treatment or cure that has been proven to halt the progress of 
the disease.  Although articular cartilage is a metabolically an active tissue, the cells 
within the matrix have a relatively slow turnover or self-healing capabilities. Its aneural 
property makes it rather impossible for it to support self-repair and remodeling. Due to 
this, injury to the tissue oftentimes leads to progressive damage and degeneration.   
Treatment such as Articular Chondrocyte Implantation (ACI) which has been a cell-
based approach in repairing articular cartilage injury is deemed better than joint 
replacement therapy which has its limitations (Alaminos et al., 2006; Redman, Oldfield, 
& Archer, 2005). The ACI treatment did not solve the problem as reports of sunken and 
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further damage to the lesion were documented (Britt & Park, 1998; Brittberg et al., 
1994; Chan & Gill, 1999; Marlovits, Zeller, Singer, Resinger, & Vecsei, 2006). 
Tissue engineering has emerged as a new technology and approach in addressing the 
problem. The basic concept is using cells of the targeted tissue, scaffold as a support 
system and bioactive molecules to direct the tissue growth and repair in order to 
fabricate functional new tissue to replace damaged ones. The use of this approach in 
cartilage repair has promoted many researchers in improving joint function and 
preventing further joint degeneration (Chung & Burdick, 2008; T. Hardingham, Tew, & 
Murdoch, 2002; Nesic et al., 2006; Redman et al., 2005).  
Tissue engineering approach involves the use of chondrocytes, 3D scaffold and 
growth factors that help in improving the repair of cartilage lesions. A variety of 
scaffold has been introduced and explored for cartilage tissue engineering applications. 
Throughout the years, various natural and synthetic materials have been investigated in 
exploring its functionality in cartilage repair. Scaffolds were regarded as promising 
materials due to its similarity in properties to the native cartilage and providing 
temporary support during cartilage repair. In addition, scaffold formulation can be 
crosslink in situ thus making it perfect to be utilized in a minimally invasive procedure 
(Cai, Liu, Shu, & Prestwich, 2005; C. D. Hoemann, Sun, Légaré, McKee, & 
Buschmann, 2005). 
Naturally, sustainable biomaterial can be explored and investigated such as 2D 
Human Amniotic Membrane (HAM) into a 3D scaffold. A novel, injectable formula 
that can be crosslink in situ has been developed for the delivery of chondrocytes and 
growth factor to the area of cartilage defects. The scaffold made from HAM and Fibrin 
as a delivery vehicle is an ideal candidate for minimally invasive procedure of cartilage 
tissue repair. 
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Previous work done by another group has shown the cytocompatibility and 
biocompatibility of 2D HAM in cartilage tissue engineering applications (C. Z. Jin et 
al., 2007). The properties of HAM that are high in collagen, hyaluronan, TGF-ß and 
cytokines, all of which can also be found in native cartilage tissues have made this 
sustainable materials a good candidate for cartilage tissue engineering scaffold. 
However, HAM is a 2D material naturally and it has been well documented that 
chondrocytes are prone to alter its phenotype in monolayer setting (Benya & Shaffer, 
1982). Due to this fact, we resorted in changing the HAM from a 2D form to a 3D form 
whilst still keeping its constituents and components intact in order to harvest its 
potential as a chondrocyte carrier/ scaffold. 
1.4 Thesis Structure 
This study is structured around the basis of understanding the tissue engineering 
concept. It is supported by previous research and findings and progressing alongside the 
evidence stated in Chapter 2.  
The experimental work is reported in two different studies; the first is optimizing the 
methods of fabricating the novel 3D scaffold specifically in procuring and changing 
HAM in a 3D scaffold and optimizing the scaffold fabrication. The next study is a 
continuation of the first study, looking into the response and the effects of chondrocyte 
culture on the 3D scaffold, the biochemical changes occurring within the in vitro 
environment, morphological changes and histological evidence of this new scaffold.  
This study is brought together in general discussion with previous results obtained 
and comparisons from other research. The present study ends with a general conclusion 
which was determined in the earlier part of the study and can be both used in clinical 
and research study purposes and as a ground for further future investigation. 
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1.5 Aims and Objectives 
1.5.1 Aim of the study 
The main aim of this study is to fabricate a new 3D scaffold from sustainable Human 
Amniotic Membrane for Cartilage tissue engineering applications. 
1.5.2 Objectives of the study 
i. To evaluate a suitable method for the production of three dimensional 
scaffolds based on HAM and Fibrin; and 
ii. To determine the feasibility of HAM/ Fibrin scaffold for chondrocyte 
proliferation and matrix production.  
 
8 
CHAPTER 2: LITERATURE REVIEW 
2.1 Introduction 
In this chapter, we discuss the previous related research on related subject matter/ 
current study in order to have a detailed understanding of the chosen study. This chapter 
focused on the cartilage itself with compact details on the anatomy, physiology, its 
pathology and current treatment. Next, we focus on the challenge of addressing suitable 
scaffold used in tissue engineering applications.  Reviews of different scaffold materials 
with different properties and choosing what deemed fit and related to the current trend 
in this field. 
2.2 Cartilage 
Cartilage is a type of connective tissues that consists of chondrocytes and ECM. It 
can be classified as specialized connective tissues (Buckwalter & Mankin, 1998). The 
basic purpose of articular cartilage is to provide a surface covering of the articular ends 
of bones at the synovial joints (M. A. R. Freeman, 1973).   
The main function of articular cartilage is being a flexible and resilient to 
compression that acts as a shock-absorber at the same time allowing a friction-free and 
smooth joint movement. The thickness of the articular cartilage may vary and usually 
can be found at around 2-4 mm depending on the area within the joints. The thickness 
remains unchanged throughout the human adult life (Fox, Bedi, & Rodeo, 2009). 
Therefore, it is unusual to become thin under normal physiological joint activity. This, 
however, differs in certain cases where a process called fibrillation occurs, where a 
localized lesion can be found on the healthy adult cartilage. This is the most common 
occurrence among the general population. Such lesion may usually lead to the thinning 
of the cartilage and finally expose the underlying covered joint ends, the subchondral 
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bones (Buckwalter, Marsh, Brown, Amendola, & Martin, 2014; Makris, Gomoll, 
Malizos, Hu, & Athanasiou, 2015; Shapiro, Koide, & Glimcher, 1993). 
Articular cartilage (AC) is devoid of nerves and is generally considered avascular. 
The tissue mainly consists of relatively small amount of chondrocytes with an 
abundance of ECM surrounding them. The cells and matrix are functionally 
interdependent, whereby the chondrocytes activity is necessary for the synthesis of 
matrix physiological degradation. In return, the matrix plays an important role in 
maintaining the cells’ homeostasis environment (Buckwalter & Mankin, 1998; Getgood, 
Bhullar, & Rushton, 2009; T. E. Hardingham & Fosang, 1995). The matrix is a form of 
a stiff gel that comprises a large amount of water (80%), a meshwork of collagen fibers, 
glycosaminoglycan (GAGs) and proteoglycans (PGs). All of these substances if 
removed by experimental procedures or under pathological conditions may cause major 
effect to the cartilage rigidity. 
The mixture of fluid and matrix allows the viscoelastic and mechanical properties 
necessary for the efficient function of the cartilage. In a healthy state, typically the 
articular cartilage has water, chondrocytes, proteoglycans and collagen (Hunziker, 
2002). The collagen and PGs are solely responsible for the load of the articular 
cartilage. The primary constituent of PGs is aggrecans with type II as a majority. ECM 
of the AC is merely 5-7% that is slowly stimulated by a single cell chondrocyte. 
However, because of its limited self-repair ability, due to the avascular and aneural in 
nature, limited repair to that partial cartilage defects may lead to future degeneration of 
the surrounding tissue is inevitable (Frenkel & Di Cesare, 2004; T. Hardingham et al., 
2002; Hunziker, 2002; Makris et al., 2015; Obradovic et al., 2001; Tuli, Li, & Tuan, 
2003). 
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The most common and abundant type of cartilage in the human body is hyaline 
cartilage. It has the ability to resist compression and tension. It mainly consists of water, 
which makes 80% of its wet weight constituent. Hyaline cartilage is abundant of type II 
collagen. It is located at the end of articulating surface joints, the nose, larynx, tracheal 
rings, bronchi and the epiphyseal plate of growing bones. Since the focus of this study is 
on articular cartilage, from this section onwards, we will only discuss on hyaline 
cartilage in particular. 
2.3 Architecture of Hyaline Cartilage 
 
Figure 2.1: Architecture and zonal classification of articular cartilage. Adapted 
from (Seal, Otero, & Panitch, 2001). 
 
AC in situ varies in shape, size and distribution according to the zone. In vertical 
sections, as shown in Figure 2.1, superficial cells appear as single and elongated oval 
outline. But in tangential to the surface, they are found to be round with a diameter of 
between 10-20 µm. In the intermediate zone, zone 2; the cells appear to be spherical 
with a diameter of 10 µm or more in singles and as it goes deeper, it occurs in groups of 
two or more. Meanwhile, in the deep zone, the cells tend to be grouped together 
vertically and resemble the cell columns  (T. E. Hardingham, 1998).  
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AC is found in the joint ends that provide smooth frictionless and stable movement 
that allows efficient load bearing and load distribution. The articular cartilage appears to 
be a simple white, avascular matrix. This highly specialized tissue comprises of a single 
cellular component the chondrocytes embedded in a highly hydrated and organized 
matrix of collagen type II and PG (T. E. Hardingham, 1998). 
2.4 Cartilage Extracellular Matrix 
The cartilage ECM plays a crucial role in maintaining the intracellular balance in 
cartilage.  It is composed of a variety of molecules such as PGs, hyaluronan, fibronectin, 
laminin and is largely dominated by collagen fibrils. Other components that can also be 
found in the ECM of cartilage is integrins which mediate the attachment between cells 
and its surrounding and plays an important role in cell signaling within the cartilage 
matrix (Gao et al., 2014).  
2.4.1 Collagen 
The cartilage matrix is comprised of the GAGs, PGs and fibers which consists of 
collagen and elastin as depicted in Figure 2.2. Collagen can be found as the most 
abundant of the connective tissue fibers. It gives cartilage the flexibility function and 
high tensile strength properties. The collagen synthesis occurs within and outside of the 
chondroblasts. There are vast types of collagen found in the human body, from Collagen 
type I to XIX (Gentili & Cancedda, 2009). 
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Figure 2.2: Extracellular matrix of articular cartilage. Adapted from (Fox et al., 
2009). 
 
Collagen fibrils are made up of aggregates of molecules known as Tropocollagen. 
Tropocollagen consists of three polypeptide chains wind around each other in a 
superhelix. In most mammalian, collagen appears to have two α1 polypeptide chains 
and one α2 polypeptide chain, which is rather different in amino acid composition 
although similar in molecular weight (Fox et al., 2009). 
The basic biological unit of collagen is not protein in molecular form but in the 
association of molecules in the form of fibril. This ability of fibril formation in the 
structure provides stability by the formation of cross-links between molecules and the 
three polypeptide chains after secretion from the cell.  The resulting network composed 
of fibrils, cross-link material, providing the material with high tensile strength. This 
unique structure makes collagen insoluble and resistant to attack by any but a specific 
enzyme so that it is metabolically inert in adult tissue (Fox et al., 2009). 
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2.4.2 Proteoglycans 
 
Figure 2.3: Structure of an aggregating proteoglycans. Adapted from (Seal et 
al., 2001). 
Chondroitin sulphate is predominant GAGs of the cartilage proteoglycans. It consists 
of a protein core which has numerous chondroitin sulphate chains attach laterally to the 
hyaluronan core as shown in Figure 2.3. The behavior and degradation reaction of 
cartilage proteoglycans are consistent with this model, thus, the core protein holds 
together many GAGs chains should be made it less vulnerable to be attacked by 
enzymes. GAGs is a general term to the carbohydrate chain, does not occur free and 
unattached to a chain. Cartilage PGs consists of two types of GAGs chain, namely 
chondroitin sulphate and keratan sulphate (Fosang & Hardingham, 1996; Gentili & 
Cancedda, 2009; Lamoureux, Baud'huin, Duplomb, Heymann, & Redini, 2007; Olsen, 
2007). 
2.4.3 Water 
In the intracellular and ECM, water accounts for approximately 70-80% of the AC 
(T. E. Hardingham, 1998). The amount of water content differs within the matrix as it 
gradually decreases from 80% in the surface to 65% in the deep zones. A temporary 
swelling of the AC attributed to the absorption of water from the joint space. The fluid 
flows from the synovial fluid transport and provides nutrients to the AC which functions 
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as lubricant to the joint. PG is responsible for fluid entrapment within the cartilage 
matrix which enables the Ac to support high loads (Eyre, 2002; M. A. R. Freeman, 
1973). Most of the water that exists in the ECM is in gel form. It navigates through the 
ECM by pressure gradient or by compression of the AC. Frictional resistance against 
the flow of fluid/ gel through the matrix is due to the low permeability of the tissue (Fox 
et al., 2009; Gao et al., 2014). The high content of PGs particularly aggrecans draws 
fluid into the AC creating a large osmotic pressure.  It is the combination of this 
resistance and pressure across the ECM that forms the mechanism enabling the AC to 
withstand significant loads up to 5 times the body weight (Paul, 1976). 
2.5 Chondrocytes 
The chondrocytes are the mature cartilage cells and are the only resident cell within 
the cartilage tissue. It is a specialized, metabolically active cell with the main functions 
in the development, maintenance and repair of the cartilage matrix (Buckwalter & 
Mankin, 1998; Choi et al., 2013; Fox et al., 2009; T. E. Hardingham, 1998). The 
chondrocytes can be found trapped in its own matrix within the lacunae. These cells can 
be identified with features of round large nucleus. The number of cells per unit volume 
of adult articular cartilage is small. It accounts for approximately 2% of the total volume 
of the AC. The chondrocytes varies in shape, size and number depending on the 
anatomical region of the AC. Those that are in the deeper regions are densely packed 
and are rounder in shape as compared to those in the superficial region which are flatter 
and smaller.  
The chondrocytes and the ECM are functionally interdependent. The chondrocytes 
activities are necessary for the synthesis of matrix physiological needs and in return, the 
matrix maintains a homeostasis environment feasible for chondrocyte activities. This 
process continues even after the completion of skeletal growth during the skeletal 
15 
development and continues throughout adult life. It has a high metabolic rate associated 
with continuous ECM turnover (Fox et al., 2009). 
2.5.1 Internal Structures 
The only resident cell within the cartilage matrix is chondrocyte. It ranges from 10-
20 µm in diameter depends on where it is located within the cartilage zones (M. A. R. 
Freeman, 1973). Like any other eukaryotic cells, chondrocytes are equipped with 
organelles such as the nucleus, rough endoplasmic reticulum (RER), golgi apparatus 
(GA) and mitochondria. The functions of these organelles are further explained as 
tabulated in Table 2.1. 
Table 2.1: List of functions of organelles found in chondrocytes. Adapted from 
(I. Freeman & Cohen, 2009; M. A. R. Freeman, 1973; Stephen W. Schaffer, 2007). 
Organelle Functions 
Nucleus Produces mRNA and transmits signals to the cytoplasm 
Rough Endoplasmic 
Reticulum (RER) 
Involved in the production of protein required to be used 
within chondrocytes 
Golgi Apparatus 
Synthesize and transport chemical substances produced 
in the chondrocytes for secretion to the ECM 
Mitochondria 
The powerhouse of the chondrocytes and produces 
chemicals that fuel for activities within the chondrocytes 
Lysosomes 
Removal of intracellular materials and involved in the 
turnover of the ECM 
 
Most chondrocytes contain cytoskeleton within their cytoplasm which can be 
identified as microfilaments, microtubules and intermediate filaments. The 
microfilaments contribute to the structural strength and contractile properties to the 
cytoplasm. It scatters within the cytoplasm and not encased by the membrane vacuole 
(M. A. R. Freeman, 1973). Meanwhile, the microtubules in the cytoplasm are 
responsible to transport the vesicle inside the cytoplasm. As adult chondrocytes neither 
divide nor it migrates, the roles of microtubules are in the cell-matrix interactions, 
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intracellular transport and in the resiliency of the chondrocyte  (Langelier, Suetterlin, 
Hoemann, Aebi, & Buschmann, 2000). It has been reported that microfilaments are 
responsible for the chondrocyte phenotype (Benya & Shaffer, 1982). 
2.5.2 Chondrocyte Metabolism 
Like any living cells, chondrocytes carry a complex chemical transformation in order 
to maintain the integrity of the cartilage tissue. As adult cartilage do not proliferate once 
matured even in the presence of growth factor, the chondrocytes are responsible for the 
sustenance of the ECM. The cartilage matrix is separated from the subchondral bone by 
the subchondral space and the nutrients for the cartilage matrix are gained through 
diffusion from the synovial fluid (Buckwalter & Mankin, 1998). Due to avascular and 
alymphatic in nature, chondrocyte has the ability to synthesize and secrete matrix in the 
avascular environment and depends primarily on anaerobic metabolism (Stockwell, 
1978). 
The chondrocytes synthesize ECM components such as the glycosaminoglycans. The 
metabolic activity of the chondrocytes can be altered significantly depending on the 
surrounding chemical and mechanical stimulation. There are pro-inflammatory 
cytokines that have an effect on the matrix synthesis and degradation such as 
interleukin-1 and tumor necrosis factor-α. Other than that, proteoglycans are also 
synthesized, maintained and secreted by the chondrocytes. These PGs are closely 
regulated by growth factors and peptides such as insulin-like growth factors, TGF-β, 
interleukin-1 and tumor necrosis factor-α (Fox et al., 2009). 
2.5.3 Chondrocyte-ECM Interaction 
The symbiosis relationship between the chondrocytes and the ECM in sustaining the 
integrity of one another is important. The interaction between these two regulates many 
biological activities crucial to the homeostasis of the cartilage. The dynamic reciprocity 
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the ECM and chondrocytes to regulate cellular activities such as cell migration, 
differentiation, matrix production and breakdown is modulated by skeletal adhesion 
molecules (Helfrich & Horton, 2006). 
Chondrocyte adhesion interaction plays a critical role in migration, proliferation and 
differentiation of cells. These adhesive interactions which are mediated by cell surface 
receptors bind to the ligands on adjacent cells or in the ECM. The intracellular signal 
transduction pathways are regulated by the integrins. There are 24 unique integrins 
dimers found in mammalian formed by 18α and 8β subunits. Integrins expressed by 
chondrocytes include fibronectin, laminin and collagen receptors. The most component 
of the chondrocytes integrins is the β1 chain (Gao et al., 2014). The β1 integrin family 
of cell surface receptors is crucial in mediating the chondrocyte –ECM interaction 
involved in cell-matrix adhesion, cell signaling, protein binding and receptor-mediated 
activities (Giancotti & Ruoslahti, 1999). 
The fibronectin receptor; α5β1 integrin together with its ligand, fibronectin plays a 
role in dedifferentiation of chondrocytes. Meanwhile, IL-1 antagonist upregulates major 
components of ECM genes and is used in the anti-inflammatory and chondroprotective 
therapy of the cartilage (Gao et al., 2014). 
The extracellular domain binds with low affinity to the ECM and the intracellular 
domain link to the cytoskeleton. These integrin molecules are freely diffuse within the 
cell membrane in their inactive state until there is an available binding domain in the 
ECM recognized. Upon ligand binding, the integrins will undergo conformational 
changes that lead to the recruitment of cytoplasmic proteins. Clustering multiple 
integrins means there will be more proteins recruited to the adhesion site with increment 
in size, adhesion strength and biochemical signaling activities (Boudreau & Bissell, 
1998; García, 2005; Garcı́a & Boettiger, 1999; Helfrich & Horton, 2006; Olsen, 2007). 
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These largely clustered integrin and cytoplasmic proteins are focal adhesion and they 
act as sensors of ECM environment thus play an important role in signal transduction. 
The type of cell-matrix adhesion organized by integrin in vitro and in vivo and the 
signal that they transduce are strongly influenced by the architecture of the ECM; 
meaning the cell probes the stiffness of its environment. The stiffness of the ECM 
dramatically affects the cellular processes and cell differentiation. Whether a cell 
proliferates or dies, it is determined by a degree which a cell physically extends the 
amount of integrin-ligand interactions. Substrate flexibility affected the size of the focal 
adhesion and the strength of the adhesion (Boudreau & Bissell, 1998; Garcı́a & 
Boettiger, 1999; Helfrich & Horton, 2006; Olsen, 2007). 
2.6 Cartilage Disorder 
The regeneration of cartilage is usually poor in adults due to its avascular nature. 
Disorders of cartilage may include: 
i. Rheumatoid arthritis: chronic, systemic autoimmune disorders; 
ii. Osteoarthritis: degenerative joint tissues due to trauma/ aging; 
iii. Achondroplasia: Autosomal dominant disorders causing disproportionate 
dwarfism; and 
iv. Chondroma: Benign tumor of the cartilage. 
There are several causes of partial or complete loss of the articular cartilage. In deep 
fibrillation, the cartilage can thin or in the worst case, completely lost which in turn 
exposing the underlying bone. In an osteoarthritic cartilage, a section of the cartilage 
can separate from the joint surface leaving a crater-like defect as illustrated in Figure 
2.4. 
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Figure 2.4: Comparison of a healthy normal joint and an osteoarthritic joint. 
Adapted from (C.Cowin & Doty, 2007). 
 
Likewise, in rheumatoid arthritis, the thinning of the underlying bone occurs. This 
resulted in severe pain and loss of joint movement affecting the Activities of Daily 
Living (ADL) of the patient. As in an acute trauma, the cartilage can be fractured or 
fully disintegrated resulting in loss of joint movement due to excruciating pain 
(Boudreau & Bissell, 1998; Clouet et al., 2009; Garcı́a & Boettiger, 1999; Helfrich & 
Horton, 2006; Hunziker, 2002; Martinek & Imhoff, 2003; Olsen, 2007; Pritzker & 
Aigner, 2010). 
These defects can be further classified as partial thickness defects and full thickness 
defects. A partial thickness defect as illustrated in Figure 2.5 (a) represents a defect 
whereby there is still some cartilage intact at the base of the subchondral bone. 
Meanwhile, deep defect as illustrated in Figure 2.5 (b) extends completely to the 
underlying calcified zone, the subchondral bone (Ritsila et al., 1994; Steadman et al., 
2003; Swieszkowski, Tuan, Kurzydlowski, & Hutmacher, 2007). 
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Figure 2.5: (a) Full Thickness defects of articular cartilage. (b) Partial thickness 
defects in articular cartilage. Adapted from (LeBaron & Athanasiou, 2000). 
 
The possibility of a cartilage defect actually depends to an extent on which type of 
defect is present. Potential repair mechanism: 
i. Intrinsic repair 
Healing of the cartilage is entirely dependent on the activity of surviving 
chondrocytes adjacent to the defect. Under this circumstance, the healing 
is an exception in adults due to the limited capacity of mature hyaline 
cartilage to self-repair. 
ii. Extrinsic repair 
In extrinsic repair, new tissue can be formed from the soft tissue spaces in 
the subarticular bone plate as new tissues can spread onto a joint surface 
from the juxta-articular region. This repair can be accompanied by the 
growth of new bone. This new cartilage often always is fibrocartilage 
rather than of the previous native hyaline cartilage.  
Among other treatment options are debridement and lavage, arthroscopy method, 
abrasion therapy and the very last resort are a total knee replacement. New methods 
introduced in repairing cartilage lesion include Autologous Chondrocyte Implantation 
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(ACI). ACI was pioneered back in 1982 by isolating rabbit chondrocytes and propagate 
them in vitro (Benya & Shaffer, 1982). 
2.6.1 Autologous Chondrocyte Implantation (ACI) 
In ACI approach, the periosteal patch is sutured in place over the defect and the 
chondrocytes were introduced underneath them as shown in Figure 2.6. Despite the 
clinical results following ACI treatment, opportunities for an improvement for these 
strategies exist as there were reported cases of drawbacks which includes the “sinking” 
of the chondrocytes patients who have been treated with ACI do not typically return to 
full physical activity until one-year post surgery. The invasive nature of the procedure 
that includes an open arthrotomy and the time interval between chondrocyte 
implantation and production of functional repaired tissue has been responsible for the 
relatively long period of patient rehabilitation. In overcoming this, the latest and current 
trend is Tissue Engineering or more recently known as regenerative medicine has been 
introduced (Britt & Park, 1998; Brittberg et al., 1994; Giannoni et al., 2005; Hamby, 
Gillogly, & Peterson, 2002; Marlovits et al., 2006; Minas & Peterson, 2012; Peterson, 
Brittberg, Kiviranta, Akerlund, & Lindahl, 2002; Trattnig et al., 2005; Vasiliadis et al., 
2010). 
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Figure 2.6: Autologous Chondrocyte Implantation procedure. Adapted from 
(Hamby et al., 2002). 
 
2.7 Tissue Engineering 
Tissue engineering can be as the structural or as functional reconstitution of cells, 
biomaterial and biological signals interplay. Challenges of this however are but limited 
to restoring the normal composition of the cartilage and restore the function of the 
damaged cartilage while avoiding future degeneration of the restored tissues (R. A. 
Brown, 2013; Chang et al., 2006; Vacanti & Vacanti, 2007). 
The emerging of tissue engineering field may be the answer to the previous 
problems. The use of cells to regenerate damaged tissues with the aid of 3D 
substrate/material to organize the cells in order to maintain tissue specific functions 
once implanted. In choosing these materials, it is obligatory to choose one that exhibits 
good biocompatibility. The biomaterial must not elicit inflammatory response or 
immunogenicity (Drury & Mooney, 2003; Frenkel & Di Cesare, 2004; Luo et al., 2014; 
Pachence & Kohn, 2000; Rosso et al., 2005; Temenoff & Mikos, 2000a; Trachtenberg, 
Kasper, & Mikos, 2014; Zhang, Ortiz, Goyal, & Kohn, 2014). 
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2.7.1 Principle Cell Sources Used In Tissue Engineering Studies 
In engineering a new functional tissue or organ, the major challenges include the 
method of acquiring the cells. The golden standard would be to mass produce the 
desired tissue and organ so that off the shelf product can be reachable to many and not 
just to the exclusive few (Ikada, 2006).  
The importance of cell source on the outcome of regenerating new tissue is very 
crucial. The cells that are applicable in tissue engineering applications may be classified 
into three different categories. The best and most ideal of cell source would be of course 
of autologous origin also known of being patient’s own. Secondly, the cells can be of 
allogeneic source meaning it is harvested from other human being or rather than another 
subject within the same species. Lastly, we can have an option from an animal source 
being xenogeneic in origin (Nerem & Schutte, 2014; Redman et al., 2005).  
The last two cell source, allogeneic and xenogeneic cell source in regenerating new 
tissue is considered to be less feasible than autologous cells due to immunologic reasons 
and the usage of these cells requires patients to undergo immunosuppressant therapy 
which is proven to be compromising the health outcome of the patient (B. N. Brown & 
Badylak, 2014; Ikada, 2006).  
2.7.2 Cells and Their Extracellular Matrix 
Monolayer culture has been the golden standard for rapid cell expansion and has 
been known to be the method used in obtaining a large number of cells of ACI 
purposes. However, the problem with cell expansion in monolayer setting is the loss of 
phenotype. The success of ACI repair was absolutely dependent on the ability of the 
implanted cells to maintain its phenotype and synthesize the cartilage matrix  (Redman 
et al., 2005). 
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In the 3D environment, chondrocytes have been reported to maintain its phenotypic 
stability because the culture environment is highly influential on the maintenance of 
chondrotypic phenotype (Holtzer, Abbott, Lash, & Holtzer, 1960). Cells have the ability 
to adjust their cytoskeleton organization, shape, motility and changes to their immediate 
environment. Integrin based adhesion complex which is associated with actin 
cytoskeleton which could recognize biochemical diversity of ECM surrounding also 
physical; and topographical characteristics. Integrin were able to sense environmental 
changes by the cytoskeletal network. Integrin are membranes that heterodimeric 
receptors that mediate communications between ECM and cells  (Olsen, 2007).  
2.7.3 Three Dimensional Scaffold 
The growing needs in tissue repair and replacements have driven tissue engineering 
strategies to provide functional alternative biological solutions. Current strategies for 
articular cartilage regeneration and repair involve the potential use of chondrocytes. 
This requires the combination of cells, biodegradable scaffold and bioactive molecules. 
The key component surrounding tissue engineering, however, is in designing a suitable 
scaffold. Up until now, there is no evidence of an “ideal scaffold” design, but each 
tissue requires specific set of properties that they must possess and this “design” should 
start with a minimum requirement  
A scaffold that is to be used in tissue regeneration must provide an environment 
necessary for cell attachment and promote adhesion, differentiation, allow nutrient and 
metabolic waste exchange and able to mimic and fulfill the final shape of the void space 
that is being replaced.  
In the first phase of cartilage tissue engineering, the fabrication and design of a 3D 
scaffold must be taken into consideration. The 3D scaffolds should be made of a highly 
biocompatible material which will not elicit violent immunological reaction to the host 
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tissue. The chosen material should be able to degrade at a controlled rate specifically to 
the nature of cell/ tissue regrowth onto the host tissue. The second phase would be the 
seeding of the viable chondrocytes onto scaffold in a static culture. This phase is usually 
done to introduce the cells to the biomaterial or 3D scaffold by incorporating the cells 
and allow attachment or adhesion to take place. Next, in phase 3, which is growing the 
cell culture in a dynamic environment, is the next phase although not all tissue 
regeneration approach requires this step. After which,  mature tissue will be introduced 
in a clinical setting in phase 4, 5 and 6 via surgical transplantation to enable surviving 
cells in in vitro environment to accommodate the desired site of the intended tissue 
repair to further allow in vivo tissue remodeling (Hutmacher, 2000). 
In order to create a 3D structure to occupy the desired cell in tissue engineering 
strategies, we need to choose the appropriate source of material for the intended 
application. Materials that are commonly used as 3D scaffold can be classified as 
organic and non-organic/ inorganic. This can be further classified as metals, ceramics 
and polymers.  
Metal is inorganic material commonly used due to their ability to conduct electricity, 
strength and easily formed into complex shapes. This material is widely used in 
cardiology, dentistry and orthopedic applications as artificial heart valves, dental 
implants/ fillings and as hip and knee replacement.  
Meanwhile, the inorganic ceramics are commonly used due to their hard properties 
and resistance to degradation in many conditions, unlike metals. It is widely employed 
as bone/ dental implant merited to its similarities to the chemistry of bone. Ceramics are 
usually chosen to cater applications acquiring small loads. 
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Unlike the two classes of materials mentioned, the polymer is an organic material 
that is extensively utilized in biomedical applications. The vast range of physical and 
chemical properties of this material has accounted for its use in the medical industry. 
Polymers can either be synthetic or man-made or naturally sourced such as protein that 
is commonly found in vivo. The common uses for these types of polymers are listed in 
Table 2.2.  
Table 2.2: Natural and synthetic polymer widely used in biomedical 
applications. Adapted from (Luo et al., 2014). 
Polymer Applications 
Synthetic  
Poly(ethylene) Orthopedic implants 
Poly(ethylene glycol) Wound dressing 
Poly(propylene) Sutures 
Poly(2-hydroxylethyl methacrylate) Contact Lenses 
Natural  
Collagen 
Orthopedic and nerve repair and tissue 
engineering matrices 
Chitosan Wound dressing 
Fibrin Hemostatic sealant 
Hyaluronic Acid Orthopedic repair matrices 
Glycosaminoglycans Orthopedic repair matrices 
 
2.7.3.1 Scaffold Criteria 
In natural tissue, the ECM that surrounds the cells in the body does not only support 
the cells but it also regulates cell proliferation, differentiation and morphogenesis. A 
scaffold should be evident to support proliferation whilst maintaining their 
dedifferentiated function. The scaffold can be from different types and variants. 
Numerous architecture shapes and texture all depending on the target tissue. Most 
feasible of the scaffold will be according to the scaffold criteria:  
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i. 3D/ porous to enable cell growth and transport of nutrients and waste 
products; 
ii. Biocompatible/ bioresorbable with controlled biodegradability while 
resorption rate match to the cell/ tissue growth in vitro/ in vivo; 
iii. Able to allow nutrient exchange and byproduct transport across the 
constructs/ native tissue; 
iv. Sufficient mechanical properties to substitute initial wound contraction 
forces, and later for the remodeling of tissues; and  
v. Manufactured in a reproducible, controlled and cost-effective manner. 
For the newly designed 3D scaffold, it is crucial for these scaffolds to be able to 
interact with the host cells in order to maintain cellular and molecular function in 
culture.  It is well known, that cells respond differently to their environment as well as 
to the architecture of their environment be it 2D or 3D, resulting in different kinds of 
response. Cell-matrix adhesion mediates physiological response responsible for cell 
growth, survival, cell migration, differentiation, and tissue organization and remodeling 
(Hutmacher, 2000; Hutmacher, Sittinger, & Risbud, 2004). Cell signaling and metabolic 
cell activation may affect cell surface interaction. Cells can sense and respond to 
chemical and physical signals from biomaterials to identify the new biomaterial traits 
that could further alter the cell behavior in vitro and in vivo (Geiger, Spatz, & 
Bershadsky, 2009). 
2.7.3.2 Scaffold Design 
In designing functional cell-support system, it is essential for it to mimic the intended 
native tissues. It must be able to retain in the space that is designated for and provide 
adequate space for cells to grow into tissues replacing the scaffold (Hutmacher, 2000; 
Temenoff & Mikos, 2000).  It must be able to provide a 3D matrix for tissue growth and 
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in-growth whilst providing shape and support to the construct being ideally exhibited 
mechanical properties similar that of the host tissue. In designing a 3D scaffold, it is 
crucial to have a porous interconnected network that would allow tissue ingrowth.  
This feature allows for nutrient delivery and byproducts to be expelled. The scaffold 
footprint should also be considered. Ideally, the resorption rate should be similar as the 
tissue regeneration. Other properties would be able to reduce fibrous tissue formation 
otherwise known as scar tissue. This is important as scarring at the site of implantation 
compromises the integrity of the host-construct interface. Lastly, the scaffold should be 
easily prepared, reproducible and sterilize while being relatively affordable for the 
patients to use (Frenkel & Di Cesare, 2004; Lu, Li, & Chen, 2013; Luo et al., 2014). 
2.7.3.3 Natural vs. Synthetic Polymer Scaffold 
The challenge in imitating nature which has the potential to be the answer to organ 
transplantation crisis and possibly address any unmet patient needs is far from reality. 
However, with recent discoveries in regenerative medicine, we are moving forward and 
closer to realizing that dream. In deeming what would be an ideal source for scaffold in 
tissue engineering application, one would have to consider the pros and the cons in each 
category and weigh the best possible outcome for the intended tissue and organ 
replacement. 
Natural materials constituents and compositions are always in the center of concern 
in designing the scaffold for tissue engineering. The two natural groups that are known 
to be natural are proteins and polysaccharides. Natural materials can be degraded by the 
embedded cells and cells, in turn, will produce new matrix to fill in the spaces formed 
by this degradation. The general fiber forming and aggregating proteins that are well 
known are collagen, fibrin and silks. Meanwhile, polysaccharides which are another 
group of natural material that can give significant mechanical strength are starch, 
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chitosan and hyaluronan (Kogan, Šoltés, Stern, & Gemeiner, 2007; Sell et al., 2010; 
Zhang et al., 2014). 
Collagen is one of the most widely used materials in tissue engineering applications. 
Collagen has been used in many physical forms, most generally known in either gel or 
sponge form. It can be used either in its native form, crosslinked, in soluble form, in an 
insoluble form and aggregated form. Generally, it can be divided into 4 categories 
which are known:  
i. Insoluble collagen 
ii. Tropocollagen 
iii. Atelocollagen 
iv. Gelatin/ heat-denatured collagen 
Insoluble collagen can be as raw as homogenized tissues, reconstitute and freeze-
dried. The structural elements of these materials are made of shredded fiber bundles. 
Tropocollagen is the intact, monomeric, acid soluble form of collagen. Atelocollagen is 
a soluble monomer rich collagen but poor in gel formation abilities due to its protein 
digesting enzymes that remove the short non-helical end extension that cuts the cross-
links. Finally, gelatin is the readily available and a more economy-friendly type of 
collagen. It is obtained by boiling the collagen hence the loss of all the triple helix 
structure and so are the tensile strength and resistance to enzyme degradation properties. 
Due to this, gelatins are poorly biomimetic, weak and bio-unstable (Boudet, Iliopoulos, 
Poncelet, & Cloitre, 2005; Pachence & Kohn, 2000). 
Hyaluronan or Hyaluronic Acid (HA) is a linear polysaccharide formed from 
disaccharide units of N-acetyl-D-glucosamine and glucuronic acid. Hyaluronan can be 
found in almost all biological fluids and tissues. HA is the simplest form of 
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glycosaminoglycan’s group substances. It occurs primarily in the ECM and the 
pericellular matrix. HA influences the cell differentiation, and tissue repair in vivo 
(Toole, 2004). 
The biological function of HA includes the elasticity and viscoelasticity of fluid 
connective tissues such as the synovial fluid, control of tissue hydration and water 
transport, molecular assembly of proteoglycans in the ECM and receptor mediated roles 
in cell mitosis, migration and inflammation (Balazs, 2009). Within the cartilage, HA 
plays a vital role in the development of cartilage the maintenance of synovial fluids and 
the regeneration of tendons. High concentrations of HA can be found in the ECM of 
adult joint tissues and in synovial fluids. HA is responsible for macromolecular 
assembly in the ECM due to the HA-protein interactions. In the synovial fluid, HA is 
responsible in providing lubrication and act as shock absorbers. It is also responsible in 
the event of signal transduction, and cell motility. Large matrix polymers of HA was 
found to be successful space fillers with properties of anti-angiogenic and 
immunosuppressive (Balazs, 2009; Kogan et al., 2007; Necas J BL, 2008). 
The unique viscoelasticity nature of HA along with its biocompatibility and 
immunosuppressive properties has led its use in multiple clinical applications as shown 
in Table 2.3. Applications of HA in orthopedic surgeries and rheumatology has been 
successful since 1980’s. The intra-articular applications of HA were reported to improve 
symptoms and decrease the use of non-steroidal anti-inflammatory drugs in patients 
suffering from osteoarthritis.  A study has suggested that the usage of HA in 
viscosupplementation could exert a therapeutic effect by restoring the elasticity and 
viscoelasticity of the loss synovial fluid and that by injecting HA can induce synthesis 
of HA by the synovial cells itself, therefore, stimulate chondrogenesis and inhibit 
cartilage degradation. The anti-inflammatory action of HA used also reduce the 
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inflammatory cell count in the synovial fluid and potentially reduce the amount of the 
reactive oxygen species content and there were also observed analgesic effect upon HA 
administration (Necas J BL, 2008).  
Meanwhile, in surgery and in wound healing applications, HA preparations are 
usually applied topically to promote healing on fresh skin wounds. Due to its anti-
oxidant properties, HA serves as an anti-inflammatory component in the wound 
dressing materials.  HA has also been used to improve and promote biocompatibility 
used in drug delivery capsules by creating a cross-link scaffold for DNA entrapment. 
HA can be obtained from various natural sources. Therefore, it is crucial in preparing 
the right formula of HA-derived therapy to address appropriate biomedical procedures 
and tissue engineering applications. The attributes of HA in clinical applications are as 
in Table 2.3. 
Table 2.3: The modalities of clinical applications of HA and its derivatives. 
Adapted from (Balazs, 2009). 
Clinical Applications HA modalities 
Viscosurgery Protect delicate tissues and provide space during 
surgical manipulations 
Viscoaugmentation Fill and augment tissue spaces, as in skin, 
sphincter muscles and vocal tissues 
Viscoseparation To separate the connective tissues surface 
traumatized by surgical procedures or injuries in 
order to prevent adhesion or excessive scar 
formation 
Viscosupplementation To replace of supplement tissue fluids such as 
synovial fluid in painful arthritis and to relieve 
pain 
Viscoprotection To protect healthy, wounded, or injured tissues 
surfaces from dryness or noxious environmental 
agents and to promote healing of such surfaces 
 
While natural polymers have its advantages, it is mechanically weak and inconsistent 
in its sources. In designing functional cell-support system, the possibility of mass 
produced and controllable properties of materials are certainly desirable. Synthetic 
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polymer has been widely explored in order to counter this downside of natural polymer 
materials. Synthetic materials such as Poly-(ortho ester) (POE), Poly-(vinyl alcohol) 
(PVA) and Poly-(ester amide) (PEA) are appealing to the scaffold design due to their 
controllable and reproducible properties and chemistry (Grishko et al., 2009). Synthetic 
materials have the ability to be incorporated with other water-soluble polymers and 
cross-link physically and chemically (Lu et al., 2013; Pachence & Kohn, 2000).  
Although synthetic polymers are reproducible and the chemical composition of the 
material can be altered significantly in order to suit its intended use, it is still lacking in 
biomimetic features that natural materials possess. The ability of natural materials to 
work as an integral part of the cell-matrix remodeling process as compared to those that 
just degrade regardless to the cells activity is what sets the two apart (Luo et al., 2014). 
2.7.3.4 Scaffold Fabrication 
Scaffold remains the central concern of researcher in tissue engineering approach.  
Previous studies have shown that fabrication methods have been applied to process 
biodegradable and bioresorbable materials into 3D scaffolds with high porosity to 
surface area as shown in Table 2.4. Although there are many available methods and 
techniques for fabricating and producing scaffolds, there is no ultimate method to 
produce specific tissue regeneration. Scaffolds meant to be used in cartilage 
regeneration have to be designed to elicit biological and materials properties compatible 
to the need of the newly formed cartilage. 
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Table 2.4: Scaffold fabrication techniques and studies. 
Fabrication 
technology 
Processing 
method 
Material 
properties 
Required for 
processing 
Scaffold design 
and 
reproducibility 
Achievable 
pore size in 
µm 
Porosity 
in % 
Architecture References 
Solvent casting in 
combination with 
particulate leaching 
Casting 
 
Soluble User, material, 
and technique 
sensitive 
30-300 20-50 Spherical pores, salt 
particles remain in 
matrix 
(Mikos, Sarakinos, 
Leite, Vacanti, & 
Langer, 1993) 
Membrane lamination 
 
 
Solvent 
bonding 
 
Soluble 
 
User, material, 
and technique 
sensitive 
30-300 < 85 Irregular pore 
structure 
 
(Widmer et al., 
1998) 
Fabrication of non-
woven 
 
 
Carding, 
needling, 
Plate 
pressing 
Fibers Machine 
controlled 
 
20-100 
 
< 95 Insufficient 
mechanical 
properties 
(Mol et al., 2005; 
Tognana et al., 
2005) 
Emulsion freeze 
drying 
Casting Soluble User, material 
and technique 
sensitive 
< 200 < 97 High volume of 
interconnected 
micropore structure 
 
(Whang, Thomas, 
Healy, & Nuber, 
1995) 
Thermally induced 
phase separation 
Casting Soluble User, material 
and technique 
sensitive 
< 200 < 97 High volume of 
interconnected 
micropore structure 
(Baker, Brown, 
Casadio, & Chirila, 
2009) 
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Table 2.4, continued. 
Fabrication 
technology 
Processing 
method 
Material 
properties 
Required for 
processing 
Scaffold design 
and 
reproducibility 
Achievable 
pore size in 
µm 
Porosity 
in % 
Architecture References 
Super-critical fluid 
technology 
Casting Amorphous Material and 
technique 
sensitive 
< 100 10-30 High volume of non-
interconnecting 
micropore structure 
 
(Harris, Kim, & 
Mooney, 1998) 
Supercritical fluid 
technology in 
combination with 
particle leaching 
Casting Amorphous Material and 
technique 
sensitive 
Micropore  
(< 50) 
Macropore 
 (< 400) 
< 97 Low volume of non-
interconnected 
micropore structure  
combined with 
interconnected 
macropore structure 
 
(Whang et al., 
1995) 
 
 
 
 
Fuse deposition 
modeling 
Solid free 
form 
fabrication 
Thermoplastic Machine and 
computer 
controlled 
> 150 < 80 100% interconnected 
macropore structure 
(triangles, pentagons, 
honeycomb, etc.) 
Design and 
fabrication layer by 
layer 
 
(Dunkelman et al., 
1995) 
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2.8 Human Amniotic Membrane 
2.8.1 Introduction 
Both natural and synthetic materials have been mass-researched throughout the use 
for tissue engineering scaffold. Concerns arise for the use of both have been discussed  
and agreed that materials that would be ideal must exhibit certain properties that may 
include good biocompatibility, biodegradable, easily obtained and demonstrates little to 
none inflammatory response to the host tissues with good mechanical properties 
depending on the placement of the scaffolds (Temenoff & Mikos, 2000b). 
In recent years, Human Amniotic Membrane has been utilized in numerous 
applications in the medical field (Bilic et al., 2005; Branski et al., 2008; Bujang-Safawi, 
Halim, Khoo, & Dorai, 2010; Liang et al., 2009; Stoddart, 2008). Successful cell-
scaffold integration depends on the type of scaffold and the ECM component of the 
scaffolds. One of the pioneers in biomaterial used as scaffold was the fetal membrane. 
Amongst the use of a fetal membrane includes; transplantation of skin, management of 
burns, reconstruction of the oral cavity, tympanoplasty, arthroplasty and bladder 
(Dell'aquila & Gaffney, 1982; Lin, Lai, Hou, & Yang, 1985). 
Human amniotic membrane has gained its importance in tissue engineering field due 
to its ability to reduce inflammatory and scarring, we enhancing wound healing and this 
served well as a scaffold for cell proliferation and differentiation as an outcome to its 
antimicrobial properties(C. Z. Jin et al., 2007; Niknejad et al., 2008).  
In addition, the ECM of the amniotic membrane such as its constituents and growth 
factors are similar to that of native cartilage thus suggesting it would be an excellent 
candidate for a 3D scaffold for this application. Moreover, this biomaterial is a 
sustainable material that can be easily attainable, transport and processed. 
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HAM develops from the extra embryonic tissue. It forms a protective barrier for the 
fetus during the gestational period. It is the innermost layer of the placenta membrane 
that is thin, elastic and translucent devoid of vascular, nerves and lymphatic vessels 
(Wilshaw, Kearney, Fisher, & Ingham, 2006). It is made up of three layers which are 
the epithelial, basement membrane and stroma. The amniotic membrane is thickness 
ranges from 20 µm to 0.5 mm.  Schematic structure of HAM is shown in Figure 2.7. 
 
Figure 2.7: Schematic structure of the HAM. Adapted from (Niknejad et al., 
2008). 
 
This natural biomaterial content is high in Collagen type I, II, III, IV, laminin and 
fibronectin (C. Z. Jin et al., 2007; Niknejad et al., 2008) . It has been utilized in 
numerous medical applications such as skin transplant to treat burns, as a wound 
dressing, in the application of ophthalmology, gynecology and regenerative medicine. 
Among other benefits that this biomaterial possess is it has natural cartilage constituents 
such as collagen, proteoglycans, and HA (Chandra et al., 2005; Díaz-Prado et al., 2010; 
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C. Z. Jin et al., 2007; Mamede et al., 2012; Niknejad et al., 2008; Wilshaw et al., 2006). 
Moreover, HAM has multiple benefits as a biomaterial that is not shared by any other 
material either natural or synthetic as shown in Table 2.5. 
Table 2.5: Properties of Human Amniotic Membrane. Adapted from (Faulk et 
al., 1980; Stoddart, 2008). 
 
  Inexpensive 
Easily 
Obtained 
Wound 
Protecting 
Reduce Pain 
Anti-
Inflammatory 
Anti-Microbial  
Anti-
Fibroblastic 
Anti Angiogenic 
Reduce 
Scarring 
Promote 
Healing 
Anti-
Tumorigenic 
Light to no 
immunogenicity 
Bacteriostatic 
Protease 
Inhibiting 
Anti 
Phlogestic 
Anti-Apoptotic 
 
 Studies have reported that this biomaterial is rich in cytokines further proving the 
study done by others for its wound protecting and scar reducing ability (Hao, Ma, 
Hwang, Kim, & Zhang, 2000; Wolbank et al., 2009). Predominantly, HAM constitutes 
of hyaluronan which is responsible for retaining fluid (Mamede et al., 2012; Meinert et 
al., 2001). HA chemical structure is as illustrated in Figure 2.8. 
 
Figure 2.8: Structure of Hyaluronic Acid. Adapted from (Necas J BL, 2008). 
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The nutrients and by-products are being transported via diffusion in HAM (Toda, 
Okabe, Yoshida, & Nikaido, 2007).  The proteoglycans; rich in heparin sulphate, actin, 
vimentin and laminin which furnish for cell survival, shape and maintenance of tissue 
phenotype are also in abundance in this biomaterial making it a potential for tissue 
engineering application (Wolbank et al., 2009). 
Another important factor that HAM possesses is the resistance to proteolytic factors 
making it better at withstanding the protein breakdown. It is known that HAM expresses 
genes that are related to cartilage such as SOX and BMP and its receptors. HAM mainly 
consists of HA which is primarily D-glucoronate and N-acetyl-D-glucosamine that is 
capable of yielding large amount of fluid. It also plays a crucial role since it is a ligand 
for Cluster of Differentiation 44 (CD44) which is an antigen expressed by inflammatory 
cells (Wolbank et al., 2009). 
HAM is suitable for allo transplantation due to its anti-inflammatory, anti-bacterial, 
anti-viral and low immunogenicity properties. A study has also reported that HAM 
reduces inflammatory mediators by entrapping the T lymphocytes. Moreover, it has also 
been reported that HAM secretes factors that inhibits both innate and immune cells 
making it  the anti-bacterial and anti-bacterial features (Bonci, Bonci, & Lia, 2005; 
Bujang-Safawi et al., 2010; Díaz-Prado et al., 2010; Hao et al., 2000; Higa et al., 2007; 
C. Z. Jin et al., 2007; J. Kim, Kim, Na, Jeong, & Song, 2000; W. Li et al., 2006; 
Mamede et al., 2012; Meinert et al., 2001). This biomaterial also produces anti-
inflammatory factors such as IL-1, IL-2 and IL-10 and endostatin that inhibits 
angiogenesis and tumor growth (Hao et al., 2000). 
2.8.2 Current Applications of Human Amniotic Membrane 
A summary of studies that looked into the effects of HAM as a biomaterial is as 
summarized as in Table 2.6. 
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Table 2.6: Summary of Human Amniotic Membrane related research. 
No. Human Amniotic Membrane-related 
research  
Findings Reference 
1.  Properties of Human Amniotic Membrane 
for potential use in tissue engineering. 
Human amniotic membrane has biological 
properties important for tissue engineering 
applications including anti-inflammatory, 
anti-scarring, anti-microbial, anti-fibrosis 
with low immunogenicity and reasonable 
mechanical property.  
 
This study also found that the ECM 
component of human amniotic membrane 
creates an almost similar to that of the 
native scaffold for cell seeding in tissue 
engineering. 
(Niknejad et al., 2008) 
 
 
2.  Amniotic membrane extracts solution for 
ocular chemical burn.  
Topical application of amniotic membrane 
extract is effective in reducing 
inflammation, promoting reepithelization in 
the treatment of ocular chemical burns 
especially in for mild to moderate acute 
cases. 
(Liang et al., 2009) 
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Table 2.6, continued. 
No. Human Amniotic Membrane-related 
research  
Findings Reference 
3.  Topical management of facial burns.  It was found that healing time and amount 
of reapplication of topical amnion dressing 
was significantly shorter in patients with 
partial thickness burns of the face, head and 
neck and a TBSA burn size under 40%. It 
showed efficacy and safety of amnion in 
burn wound healing in an exclusively 
paediatric population. 
 
(Leon-Villapalos, Jeschke, & 
Herndon, 2008) 
 
 
 
4.  Human amniotic membrane as a deliver 
matrix for articular cartilage repair. 
It was found that denuded human amniotic 
membrane could be one of the ideal cell 
carrier matrices for cartilage regeneration. 
 
(C. Jin et al., 2007) 
 
 
  
 
4
1
 
Table 2.6, continued. 
No. Human Amniotic Membrane-related 
research  
Findings Reference 
5.  Autologous amnion graft for repair of 
myelomeningocele: technical note and 
clinical implications.  
 
A novel repair technique using autologous 
amnion graft and successfully treated 
myelomeningocele. The postoperative 
healing process of the wound was excellent. 
The amniotic tissue has no risks of 
rejection, foreign body reaction, or 
transmission of slow virus infection to 
reconstruct the lesion of newborn patient. 
The amnion autograft promote wound 
healing, being applied as a part of a variety 
of paediatric neurosurgical procedure. 
 
(Hasegawa, Fujisawa, Hayashi, & 
Yamashita, 2004) 
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Table 2.6, continued. 
No. Human Amniotic Membrane-related 
research  
Findings Reference 
6.  Interleukin-1 receptor antagonist (IL-1RA) 
prevents apoptosis in ex vivo expansion of 
human limbal epithelial cells cultivated on 
human amniotic membrane.  
This study found that human amniotic 
membrane may prevent apoptosis in ex vivo 
expanded human epithelial cultivated on 
amniotic membrane. 
 
(Sun et al., 2006) 
7.  Sterilized, freeze-dried amniotic membrane: 
A useful substrate for ocular surface 
reconstruction.  
 
The sterilized and freeze-dried amniotic 
membrane retained most of the physical, 
biological and morphological characteristics 
of cryopreserved amniotic membrane and 
deemed useful as a biomaterial in ocular 
surface reconstruction. 
(Nakamura et al., 2004) 
 
 
8.  Proteoglycans and Hyaluronan in human 
fetal membrane.  
The study found that the fetal membrane 
contains high concentration of collagen, 
proteoglycans and Hyaluronan. 
(Meinert et al., 2001) 
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2.9 Fibrin 
2.9.1 Introduction 
Fibrin is an organic polymer that has been studied for its many functional properties 
in the medical field. Fibrin is a natural polymer scaffold that has been thoroughly 
researched (Bensaı̈d et al., 2003; Bhardwaj et al., 2011; Dainiak et al., 2010; des Rieux, 
Shikanov, & Shea, 2009; Eyrich et al., 2007; Hall, 2010; Ho, Cool, Hui, & Hutmacher, 
2010). It is the first known biomaterial to mankind, naturally occurring when there is an 
injury in the body, forming biodegradable matrix within the human blood at the site of 
contact.  Its long list of use as a biomaterial, pose a great advantage as it attaches to 
most biological surfaces with no adhesion problem. Fibrin can be autologously-derived 
therefore it is highly reproducible. It is well known that it helps in wound healing and 
the fibrin clot characteristics can be altered significantly by adjusting and manipulating 
the concentrations of its components. The degradation rate of fibrin can be adjusted and 
controlled with the help of fibrinolysis inhibitor (Plug & Meijers, 2016). The 
polymerization can be significantly altered by its components to the desired physical 
structure either of thin or thick fiber (Akpalo & Larreta-Garde, 2010; Shaikh et al., 
2008). 
Fibrinogen is the precursor of fibrin matrix in every blood clot process. When blood 
clots, as shown in Figure 2.9, fibrin immediately self-aggregates to form a fibrillary gel, 
then it progressively crosslinks to form dense gel material. Polymerization of fibrinogen 
and thrombin as illustrated in Figure 2.10 with the aid of physiological enzyme, is rapid 
and convenient (can be injected directly into tissue spaces). Cells seeding can be done at 
the moment of fibrin fiber formation; therefore the cells are trapped inside the fiber 
meshwork as they would be in in vivo environment. This is a great advantage as the 
time needed for cell seeding or infiltration is zero and homogenous cell dispersion can 
be achieved (Eyrich et al., 2007; Harold A, 2004).  
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Figure 2.9: Simplified fibrin adhesion cascade. Adapted from (Blann, Landray, 
& Lip, 2002). 
 
 
Figure 2.10: Signaling pathway of a fibrin clot. Adapted from (Blombäck & 
Bark, 2004; Harold A, 2004; Schwartz, Pizzo, Hill, & McKee, 1973). 
 45 
 
2.9.2 Current Applications of Fibrin in Tissue Engineering 
Fibrin has long served as a biomaterial in numerous biomedical applications and is 
comparable to an ideal scaffold as shown in Table 2.7. Due to its vast availability and 
ease of procurement and manufacturing, it has been utilized in most scaffold research as 
tabulated in Table 2.8. Not only can it cater to patients own blood, it has amazing 
advantages among of which are major concerns with other biomaterials. Lacking in 
mechanical properties may be its major disadvantage but not all applications require 
such criteria. Currently, in this study, we are not focusing on the biomechanical aspect 
of this scaffold, as we are more concern on the feasibility of the scaffold that involves in 
supporting chondrocytes proliferation and ECM production. 
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Table 2.7: Desirable features of an ideal scaffold comparable to fibrin gels scaffold. 
Ideal Characteristics Fibrin Characteristics References 
Biocompatible 
Non-Toxic 
Non-Allergic 
Non-Inflammatory 
 
Fibrin-based biomaterials have high 
affinity to various biological surfaces 
and are already in clinical use 
(Bensaı̈d et al., 2003; 
Wozniak, 2003; Ye et 
al., 2000) 
Biodegradable 
Controlled and 
adjustable 
biodegradation 
allowing sufficient 
time for new tissue 
formation 
Biodegradation can be easily 
controlled with the use of cross-
linking of fibers or using inhibitors 
of fibrinolysis 
(Mol et al., 2005; 
Wozniak, 2003) 
Autologous Nature 
Non-immunogenic 
No foreign body 
rejection 
Fibrin can be autologously harvested 
from patients’ own blood, limiting 
immune and foreign body rejection 
(Aper, Schmidt, 
Duchrow, & Bruch, 
2007; Jockenhoevel et 
al., 2001; Ye et al., 
2000) 
Biological Nature 
Fibrin is a provisional matrix in 
normal wound healing, its structural 
and biochemical properties make it a 
promising candidate as a scaffold in 
tissue engineering 
(Rowe, Lee, & 
Stegemann, 2007) 
Three-Dimensional 
Assisting cell growth 
Permitting easy 
diffusion of nutrition, 
gas transport and 
waste product 
Offer excellent cellular growth and 
tissue development in 3D matrix 
structure 
(Aper et al., 2007; 
Rowe et al., 2007; Ye 
et al., 2000) 
Easily processable 
Manufactured in less 
time 
Reproducible 
Can be easily produced from 
patients’ own blood and are 
completely reproducible 
(Aper et al., 2007; 
Rowe et al., 2007; Ye 
et al., 2000) 
Economical 
Affordable to all 
Being natural and autologous 
scaffold, the cost would be affordable 
to all 
(Flanagan et al., 2007) 
Variable in shape and 
size 
Possible to construct fibrin scaffold 
to fill any desired shape and size 
Can also be used as an injectable 
scaffold 
(Jockenhoevel et al., 
2001) 
Adjustable chemical, 
physical and 
mechanical properties 
The compliance and polymerization 
rate of fibrin can be controlled by 
varying ionic strength and the 
concentration of fibrinogen and 
thrombin 
(Eyrich et al., 2007; 
Kjaergard & Weis-
Fogh, 1994; Rowe et 
al., 2007) 
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Table 2.8: Summary of Fibrin scaffold related research. 
No. Fibrin scaffold-related research  Findings Reference 
1.  The effect of in vitro culture on a fibrin glue 
hydrogel embedding swine chondrocytes. 
The chondrocytes survived in the fibrin glue gel 
and enhanced their synthetic activity. 
(Scotti et al., 2010) 
2.  The influence of fibrin based hydrogels on 
the chondrogenic differentiation of human 
bone marrow stromal cells.  
The use of fibrin for cartilage repair facilitates 
Bone Marrow Stem Cells (BMSC) chondrogenesis 
and cartilaginous growth in an osteochondral 
environment. 
(Ho et al., 2010) 
3.  The effect of Gelatin-Fibrinogen cryogel 
derma matrices for wound repair.  
In vitro studies demonstrates Gelatin-Fibrinogen as 
a good potential as matrices for wound healing. 
(Dainiak et al., 2010) 
4.  The study of Fibrin hydrogels for non-viral 
vector delivery in vitro.  
The inclusion of non-viral vectors into fibrin-based 
hydrogels can induce transgene expression of 
encapsulated and infiltrating cells and may be 
employed with in vitro models for tissue growth to 
alter the intrinsic bioactivity of fibrin. 
(des Rieux et al., 2009) 
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Table 2.8, continued. 
No. Fibrin scaffold-related research  Findings Reference 
5.  Fibrin as a Delivery System for 
Therapeutic Drugs and Biomolecules.  
In depth reviews of the advantageous biological aspects 
of fibrin, the history of the scaffold material, and its 
present role in the delivery of drugs, growth factors, 
cells, and gene vectors. 
(Breen, O'Brien, & Pandit, 
2009) 
6.  The effect of chondrocytes implantation 
in Fibrin-Hyaluronan matrix.  
The MRI findings showed good filling of the defect with 
tissue having the imaging appearance of cartilage in all 
patients. Level of Evidence: Level IV, Therapeutic study. 
(Nehrer, Chiari, Domayer, 
Barkay, & Yayon, 2008) 
7.  A fibrinogen-based microporous 
scaffold for cartilage tissue engineering. 
The use of Acetone and genipin to improve the 
biomechanical strength of Fibrinogen based scaffold. 
(Linnes, Ratner, & Giachelli, 
2007) 
8.  Resurfacing potential of heterologous 
chondrocytes suspended in Fibrin glue 
in large full-thickness defect of femoral 
articular cartilage.  
 
Isolated heterologous chondrocytes can be used for 
transplantation in articular cartilage defects; however, 
fibrin glue does not offer enough biomechanical support 
to the cells to maintain its function as a three-
dimensional scaffold as newly formed tissue was 
observed with subsequent replacement by fibrous tissue. 
 
(Wood et al., 2006) 
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Table 2.8, continued. 
No. Fibrin scaffold-related research  Findings Reference 
9.  The long term stable fibrin gel for cartilage 
engineering.  
A coherent cartilaginous was obtained and was 
homogenously distributed throughout the 
construct suggesting stable fibrin gel are 
desirable for other tissue engineering 
applications. 
(Eyrich et al., 2007) 
10.  A study on the construction of a complete 
rabbit cornea substitute using fibrin-agarose 
scaffold.  
All three types of corneal cells cultured, 
expanded and used in constructing a full 
thickness cornea substitute. 
(Alaminos et al., 2006) 
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2.10 Summary of Literature Review 
Numerous studies related to HAM as mentioned in Table 2.6 have centered on the 
advantages of its many properties. Although a study has been done on denuded human 
amniotic membrane as a cell carrier for cartilage regeneration (C. Z. Jin et al., 2007), it 
has been well documented that monolayer culture of chondrocytes resulted in the loss of 
the chondrocytic phenotype and replaced by a complex collagen phenotype consisting 
predominately of type I collagen and reduction of proteoglycans production (Benya & 
Shaffer, 1982). However, there is yet to be a study to assess the feasibility of a 3D HAM 
scaffold for cartilage tissue engineering application. This study of HAM/ Fibrin scaffold 
incorporated the use of fibrin as a binding agent in order to assess the feasibility of 3D 
HAM/ Fibrin scaffold for cartilage tissue engineering application as this study progress 
in Chapter 3, 4 and 5. 
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CHAPTER 3: METHODOLOGY 
3.1 Introduction 
In this chapter, the methods which were utilized in conducting the experiments are 
explained, starting off with the descriptions of medium and enzymes used, cell isolation 
method, procurement of amniotic membrane, processing of the amniotic membrane into 
powder form, fabrication process of HAM/ Fibrin scaffold, descriptions of biochemical 
assays, live/dead assay, scanning electron microscopy and histological evaluation. This 
chapter also explains the type of statistical analysis used to assess the results. 
3.2 Culture Medium and Enzymes 
In previous cartilage tissue engineering studies, there were a few different forms of 
chondrocyte culture medium preparation. The method in the present work was first 
optimized and then utilized in all of the experiments. Table 3.1 shows the detailed 
composition of chondrocyte culture medium. In this study, chondrocyte culture medium 
is known as Dulbecco’s Modified Eagle Medium (DMEM) + 20% Fetal Bovine Serum 
(FBS). 
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Table 3.1: Composition of chondrocyte culture medium. 
Medium / Chemical Quantity Concentration Catalogue No 
Dulbecco’s 
Modified Eagle 
Medium (D5901) 
500 ml Stock 
D5921, Sigma 
Aldrich 
Fetal Bovine Serum 
(FBS) 
100 ml Stock 
F9665, Sigma 
Aldrich 
Hepes-Buffer 10 ml 16 mM 
H0887, Sigma 
Aldrich 
Penicillin/ 
Streptomycin 
10 ml 16 mM 
P4333, Sigma 
Aldrich 
ε-Aminocaproic 
Acid
1
 
Stock 20 mM 
A2504, Sigma 
Aldrich 
L-Glutamax 5 ml 1.6 mM 
35050-061, 
Invitrogen 
L-Ascorbic Acid 0.075 g 0.068 mM Duchefa Biochemie 
ε-Aminocaproic 
Acid 
Stock 5 mM Sigma Aldrich 
  
Enzymes used for pre-digestion of cartilage matrix are as shown in Table 3.2. 
Table 3.2: Enzymes used in pre-digestion of cartilage matrix. 
Enzyme Quantity Concentration Catalogue No 
Protease 10 ml 
20 U/ml prepare 
in DMEM + 20% 
FBS 
P8811, Sigma Aldrich 
Collagenase 
Type II 
30 ml 
200 U/ml prepare 
in DMEM + 20% 
FBS 
Worthington, USA 
                                                 
1 ε-Aminocaproic Acid is supplemented solely for the HAM/Fibrin and fibrin scaffolds culturing medium. 
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3.3 Chondrocyte Isolation 
Bovine joints of a year old Bhramal Cross were obtained from a local abattoir and 
the cartilage was harvested from the metacarpal-phalangeal joint within the same day 
under aseptic conditions as in Figure 3.1 (a) and (b). The finely-minced cartilage was 
temporarily kept in DMEM + 20% FBS as in Figure 3.1 (c) before being subjected to 
enzymatic digestion. The process was then continued to the pre-digestion of the 
harvested cartilage with 20 U/ml Protease for an hour at 37°C and 5% CO2 and 
subsequently in 200 U/ml collagenase type II for 16 hours as in Figure 3.1 (d). 
 
Figure 3.1: Bovine chondrocyte isolation method. (a) Metacarpal-phalangeal 
joint. (b) Exposed metacarpal-phalangeal joint. (c) Minced cartilage chips in 
DMEM + 20% FBS. (d) The resultant supernatant containing chondrocytes. 
 
3.3.1 Cell Count and Viability 
For the cell count and cell viability, the method used was the standard Trypan blue 
dye exclusion assay with the aid of a haemocytometer. A sample of 20 µl of cell 
suspension from the isolated cells was mixed with an equal amount of prepared Trypan 
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blue solution at a ratio of 1:1 (v/v). A standard method to equate the number of cells in 
1 ml cell suspension from the 20 µl that we tested is as Equation 3.1. 
  
 
3.4 Procurement of Human Amniotic Membrane 
Human placentas were obtained immediately after birth in accordance with the tenets 
of the Declaration of Helsinki and with approval from the Ethical Committee, 
University Malaya (Reference No: 751.26) (Appendix B) from ten elective Caesarean-
sectioned mothers who were tested seronegative for HIV, Hepatitis B and C and 
Syphilis. The placentas were processed under stringent sterile conditions. The HAM 
was peeled carefully from the chorion part of the placenta and was washed several times 
in Phosphate Buffered Saline (PBS) supplemented with 100 U/ml Penicillin and 100 
µg/ml of Streptomycin to remove blood clots. Remaining blood clot and mucus was 
gently scraped off by using a Techno-Plastic-Products (TPP) cell scraper (Trans-Techno 
Enterprise). The HAM was then washed several times by gentle agitation on a shaker 
platform in sterile normal saline as shown in Figure 3.2 (a) – (e). The membranes were 
stored in a gradual increment of glycerol every day up to 85% from 20%. They were 
then stored in 85% glycerol at 4°C until further use (Ravishanker, Bath, & Roy, 2003). 
Equation 3.1: The Naubauer Ruling 
Number of cell per ml 
= Number of cell per mm3 * dilution factor * 104 
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Figure 3.2: Procurement of HAM. (a) The procured placenta. (b) Peeling/ 
separation of HAM from the chorionic membrane. (c) Procured HAM. (d) 
Irrigation of HAM with PBS supplemented with Penicillin/ Streptomycin. (e) HAM 
in glycerol for storage. 
 
3.5 HAM Extracts Production 
Following meticulous irrigation, the HAMs were then cut into smaller pieces ~1 cm
2
 
each and then frozen in liquid nitrogen. These HAMs were then pulverized in the 
Biopulverizer (Bio Spec Products Inc.) before being homogenized in the Homogenizer 
(Bio Spec Product Inc.) in a homogenizing medium that consists of PBS and  Protease 
Inhibitor cocktail (P8340 - Sigma Aldrich). The homogenized HAMs were then further 
frozen at -20°C, and then -80°C, before being lyophilized at -50°C at 85 Pa overnight. 
The resultant extracts were pre-weighed (0.5 g) and packed before they were sent for γ-
sterilization (25 kGy) at the Malaysian Institute of Nuclear Technology, Bangi, 
Malaysia. Figure 3.3 summarizes the HAM extraction process. 
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Figure 3.3: Workflow of HAM extracts production. 
 
3.6 Fabrication of HAM/ Fibrin scaffold 
The HAM/ Fibrin scaffold has never been explored before by anyone, therefore 
several protocols have been developed in order to explore the optimum concentration 
for the HAM/ Fibrin scaffold. The protocol for HAM/ Fibrin scaffold optimization is as 
shown in Table 3.3. 
Human Amniotic 
Membrane 
Cut into small pieces (±1 cm) 
Immerse in liquid 
nitrogen 
Pulverize into smaller 
pieces 
Superspin at 15,000 x g 
Collect supernatant 
Freeze-dry at 85 Pa 
overnight 
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Table 3.3: HAM/ Fibrin scaffold optimization protocol. 
Cell number (millions/ ml) HAM : Fibrin (v/v) Setting Time (minute) 
1  0.5:1 
30 
45 
60 
3  1:1 
30 
45 
60 
5  1:0.5 
30 
45 
60 
 
Following the cell count and cell viability tests, a final concentration of 
approximately 10 million cells per ml was prepared in suspension. These cell 
suspensions were mixed carefully with the aid of 21 G needles. Bovine fibrinogen of 
Type I-S (P8630, Sigma Aldrich) was dissolved in 0.9% NaCl at 37°C for 2 hours at 
200 mg/ml. The prepared fibrinogen solution was mixed carefully with cells and HAM 
according to Table 3.3, and then it was mixed simultaneously with thrombin at a final 
concentration of 2.5 U/ml in 20 mM CaCl2.  After optimization, the HAM/ Fibrin 
scaffolds were prepared at a concentration of 1:1 (v/v) ratio. The scaffolds were then 
allowed to polymerize in a custom-made 316L stainless steel mould with an inner 
diameter of 5 mm and 5 mm thickness at 37°C and 5 % CO2 as shown in Figure 3.4. 
The preparation procedure resulted in an optimized HAM/ Fibrin scaffold with a 
final concentration of 50 mg/ml with a thrombin concentration of 2.5 U/ml, CaCl2 at 20 
mM, and ~5 million/ml chondrocytes. Fibrin scaffolds, as the experimental control, 
were fabricated from the same concentration but without any presence of HAM. The 3D 
scaffolds were transferred into 24-well plates (NUNC Brand, Thermo Fisher) with 1 ml 
of chondrocyte culture medium per well as prescribed earlier, but supplemented with 5 
mM of ε-Aminocaproic Acid that was refreshed every other day.  
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Figure 3.4: (a) 316L Stainless steel custom made mould. (b) Polymerization of 
scaffolds in the 316L stainless made mould. (c) HAM/ Fibrin scaffold. 
 
3.7 Biochemical Assay 
3.7.1 Digestion of HAM/ Fibrin Scaffold 
Assessments of the scaffolds were done at 4 different time-points, beginning at day 
7, followed by day 14, 21 and 28. The 3D construct was removed from the static culture 
and then were transferred to the Biosafety Cabinet for further characterization and 
analysis. The 3D construct had to undergo an enzymatic digestion prior to total GAG 
and DNA quantification assessment. The protocol used was adapted (C. D. Hoemann, 
2004). 
The 3D construct was cut into halves (transversely) and transferred to a 
microcentrifuge tube. Then 250 µl of digestion enzyme with a concentration of 2.5 U/ml 
of Papainase (Sigma Aldrich) in 20 ml of sterile Phosphate Buffer EDTA (PBE) 
supplemented with 63 mg of L-Cysteine Hydrochloride was added. The scaffolds were 
left in the oven overnight at 60°C. Next the digested scaffolds were then centrifuged at 
10,000 x g for 5 minutes at room temperature before being assessed for DNA and GAG 
contents (C. D. Hoemann, 2004). 
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3.7.2 Deoxyribonucleic Acid (DNA) Assay 
DNA content was assessed immediately following overnight enzymatic digestion of 
scaffolds. This is due to depletion in DNA content over time and sample freezing (C. D. 
Hoemann, 2004). Post scaffolds digestion, the DNA contents were assessed by using the 
Hoechst 33258 assay. The Hoechst 33258 dye is DNA specific and exhibits 
fluorescence upon binding with bovine DNA. A DNA stock standard solution was made 
of Deoxyribonucleic Sodium Salt from Calf Thymus (Sigma Aldrich) with a 
concentration of 2 mg/ml, which was prepared  (C. D. Hoemann, 2004). The DNA 
working solutions were prepared with TEN Buffer (10 mM Tris-HCl, 1 mM EDTA and 
100 mM NaCl, pH 7.5) (Caroline D. Hoemann; Y. J. Kim, Sah, Doong, & Grodzinsky, 
1988).          
The DNA of the digested scaffolds was analyzed by further diluting the stock 
standard solution to the initial standard concentration of 12.5 µg /ml. Then serial 
double-dilutions were prepared with PBE until the final concentration of 0.391µg/ml 
achieved. In triplicate in the first 3 columns, 10 µl of each blank, standards and samples 
were subjected to 200 µl working solution with the aid of multichannel pipette in the 96 
well (NUNC Brand) with a layout as indicated in Table 3.4. PBE buffer was used as 
blank. The DNA fluorescence reading was accessed immediately by using a microplate 
fluorometer (FLUOstar Optima, BMG Labtech) at 360 nm excitation and 460 nm 
emission wavelength (C. D. Hoemann, 2004).  
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Table 3.4: Orientation of Blanks (B), Standards (S) and Samples (X) for DNA/ 
GAG analysis. 
 1 2 3 4 5 6 7 8 9 10 11 12 
A B B B  X1 X1 X1  X8 X8 X8  
B S1 S1 S1  X2 X2 X2  X9 X9 X9  
C S2 S2 S2  X3 X3 X3  X10 X10 X10  
D S3 S3 S3  X4 X4 X4  X11 X11 X11  
E S4 S4 S4  X5 X5 X5  X12 X12 X12  
F S5 S5 S5  X6 X6 X6  X13 X13 X13  
G S6 S6 S6  X7 X7 X7  X14 X14 X14  
 
3.7.3 Glycosaminoglycans (GAG) Assay 
The amount of GAG produced inside the scaffold matrix was assessed by using the 
Dimethyl-Methylene Blue (DMB) assay, a strong metachromatic dye for histochemical 
detection of sulphated GAGs. The digested scaffolds can be assessed immediately or up 
to a week from the day that it has been fully digested.  The DMB assay was prepared 
prior to the GAG quantification. 16 mg of Dimethyl Methylene Blue (DMB) was 
dissolved in 5 ml of ethanol (Sigma Aldrich,) in a dry vial, kept under foil and stirred 
with a magnetic stirrer (WiseStir MSH10, Daihan Sci.) for 2–16 hours until fully 
dissolved (C. D. Hoemann, 2004). 
In a separate Duran bottle, 2.37 g of NaCl and 3.04 g of Glycine were added to 900 
ml double distilled water. Then, the dissolved DMB was added to the NaCl-Glycine 
solution. The remaining DMB was washed with 200 µl ethanol rinse. The pH of the 
final solution was adjusted by using 1N HCl to pH 3.0. The solution was brought to a 
final total volume of 1 liter with double distilled water. The final solution was then 
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filtered before being stored in a foil-wrapped bottle at room temperature (C. D. 
Hoemann, 2004). 
The GAG contents from the digested samples were quantified by comparing the 
fluorescence values from the Chondroitin-6-sulphate standard. The Chondroitin-6-
sulphate was mixed at a concentration of 1 mg/ml in a 50 ml conical tube with distilled 
water.  In order to generate a series of standard curves, the initial standard concentration 
of 200 µg/ml was set, followed by serial dilution until the final concentration of 6.25 
µg/ml. The serial dilution was achieved by diluting the standard stock solution of 1 
mg/ml with PBE. Triplicate 10 µl samples of each standard solution, blanks and 
samples were subjected to 250 µl of DMB solution in accordance to the layout as 
mentioned in Table 3.3 in a 96 well plate (NUNC Brand). dH2O and DMB were used as 
blank. The Fluorometer microplate reader (FLUOStar Optima, BMG Labtech) was used 
to read the absorbance level. The microplate fluorometer reader was set to read 
absorbance between 520 and 590 nm wavelength (Caroline D. Hoemann). 
3.8 Live/ Dead Assay 
The 3D scaffolds were pre-washed with PBS before being cut sagittally in halves and 
incubated at room temperature for about 15 - 45 minutes in 1 ml of DMEM (Sigma 
Aldrich) supplemented with 4 µM of Calcein-AM (17783, Sigma Aldrich, Malaysia) 
and 1 µM of Ethidium Homodimer (46043, Sigma Aldrich) before proceeding with the 
scanning (Benjamin Gantenbein-Ritter, 2008). The scaffolds were then scanned from 
their top to bottom surface at ~50 µm depth at random locations with a confocal laser 
microscope (Leica TCS SP5 II) with a magnification of 500X. 
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3.9 Histological Staining 
The samples were also subjected to histological staining to view the microstructure 
of the scaffolds. The samples were fixed in neutral buffered saline for 24 hours prior to 
processing. After that, the samples were subjected to a series of dehydration and 
rehydration processes, in order to further fix the cells in the scaffold and avoid the 
possibilities of the cells from being washed off during the staining processes. The 
processed samples were then embedded in paraffin. The embedded samples were 
sectioned thinly (~5 µm) with a microtome. Prior to the histological staining of the 
sectioned samples, the Safranin-O stains were prepared as according to Table 3.5. The 
sectioned samples were then pretreated with serial alcohol dehydration and rehydration 
followed by a staining process as detailed in Table 3.6. 
Table 3.5: Safranin-O staining preparation. Adapted from (Schmitz, Laverty, 
Kraus, & Aigner, 2010). 
 
Reagent Composition 
Wiegert’s Hematoxylin solutions 
Solution A: 1% Hematoxylin in 95% 
Alcohol 
Solution B: 30% Ferric chloride 
(anhydrous) – 4 ml 
Concentrated HCl – 1 ml 
Distilled water – 95 ml 
Add equal parts of A + B mix and use 
immediately 
0.001% Fast green (FCF) solution 
Fast green : 0.01 g 
Distilled water: 1000 ml 
1% Acetic Acid 
Acetic acid glacial: 1 ml 
Distilled water: 99 ml 
0.1% Safranin-O Solution 
Safranin-O: 0.01 g 
Distilled water: 100 ml 
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Table 3.6: Safranin-O staining protocol. Adapted from (Schmitz et al., 2010; 
Tran et al., 2000). 
Reagent / Chemical Time (minutes) 
Xylene 4 
Xylene 4 
Xylene 4 
96% Ethanol 1 
96% Ethanol 1 
70% Ethanol 1 
Tap water rinse 1 
Weigert’s working solution 10 
Running tap water 10 
Fast green (FCF) solution 5 
1% acetic acid solution  10-15 seconds 
0.1% Safranin-O solutions 5  
100% Ethanol 5 
100% Ethanol 5 
100% Ethanol 5 
Xylene 5 
 
After the staining process, the samples were held onto the slides by covering them 
with a coverslip, with the aid of DPX mountant (Sigma-Aldrich), before viewing them 
with a standard light microscope. 
 
3.10 Field Emission Scanning Electron Microscopy (FESEM) 
Both the structure and morphology of the scaffolds were observed using FESEM. 
The samples were processed prior to FESEM viewing as tabulated in Table 3.7. 
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Table 3.7: FESEM sample preparation protocol. 
Chemicals / Reagents Time (minutes) 
Glutaraldehyde 15 
Osmium Tetroxide (2%) 15 
Dilute with H2O 15 
10% alcohol 15 
20% alcohol 15 
30% alcohol 15 
40% alcohol 15 
50% alcohol 15 
60% alcohol 15 
70% alcohol 15 
80% alcohol 15 
90% alcohol 15 
100% alcohol 15 
100% alcohol 15 
3 parts ethanol: 1 part acetone 15 
1 part ethanol: 1 part acetone 15 
1 part ethanol : 3 part acetone 15 
Absolute acetone (3X’s) 20 
 
These processes were followed by a process called Critical Point Drying (CPD) 
where the samples were mounted on a stub and were held under vacuum conditions in a 
CPD machine (Biorad) to eliminate any traces of water before being coated with gold in 
the gold sputter machine (Polaron). Finally, samples were viewed with the FESEM 
machine (Qanta FEG 450) with a magnification of 500X. 
3.11 Statistical Analysis 
The results are expressed as mean ± standard error. A two-sample t-test was used to 
determine the significance of the number of day’s culture between the two scaffolds. 
Statistical significance was assessed by ANOVA and the Scheffe post hoc test at a level 
of p< 0.05 using SPSS 20.0 software to determine the cell proliferation of the two 
scaffolds for different days. 
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3.12 Summary of Research Methodology 
Throughout this chapter, the study revolves around numerous methods that have 
been simplified as depicted in Figure 3.5. 
 
Figure 3.5: Summary of Research Methodology 
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CHAPTER 4: STUDY 1 - HAM/ FIBRIN CONSTRUCTS FABRICATION & 
OPTIMIZATION 
4.1 Introduction 
Due to the limited capacity of self-repair, minor injury to the cartilage often progress 
further, damaging the surrounding healthy tissues and leads to degeneration. The lack of 
effective treatments to address this matter leads to new approaches in articular cartilage 
repair. Engineering functional cartilage tissue involves the combination of cells, 
scaffold and bioactive molecules. The choice of scaffold used is crucial in determining 
the outcome of the engineered cartilage. Numerous studies have been done on different 
types of materials to access the feasibility for various tissue engineering applications.  
In our current study, HAM has been chosen due to its many credentials. Other than 
being widely available at 4.2 births per seconds worldwide, HAM is usually discarded 
following childbirth hence the ease of availability. Furthermore, HAM was not only 
feasible due to its tremendous list of advantages as a biomaterial in tissue engineering 
applications (Branski et al., 2008; Bujang-Safawi et al., 2010; He et al., 2009; Oxlund, 
Helmig, Halaburt, & Uldbjerg, 1990; Ravishanker et al., 2003; Rodríguez-Ares et al., 
2009; Sun et al., 2006) , it also comprises of similar constituents of that in native 
cartilage which made it more appealing in cartilage tissue engineering. 
The HAM is a 2D film like sheet that has been used in many research fields as 
scaffold mainly in plastic surgery and ophthalmology.  The fact that chondrocytes tend 
to change its phenotype in 2D architecture has tempted this research to change the 2D 
environment of HAM to cater chondrocytes to this amazing biomaterial without 
compromising its phenotype (Benya & Shaffer, 1982). 
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In this chapter, we were evaluating the optimized concentration of HAM/ Fibrin 
constructs in order to proceed with other evaluations. One of the main aspects that 
revolved around Tissue Engineering is the 3D scaffolds. The main issues concerning 
this scaffold are its biocompatibility, biodegradability and cytotoxicity. The 3D 
scaffolds act as a matrix that sends signaling cues to the surrounding cells on how to 
behave and organize. It is important that these scaffolds meet certain criteria while at 
the same time, optimized with the right amount of cells in order for it to play its part in 
vitro before we could proceed in evaluating them in vivo. 
Currently, there are no studies being done on the effect of turning 2D HAM into 3D 
forms, let alone optimizing it. We are looking into studying the 3D form of HAM 
incorporated with fibrin and optimizing it in return of studying the effects of these 
constructs on cartilage tissue engineering applications.  
Optimization of this newly developed construct involves both the material and the 
isolated cells simultaneously. This will be elaborated in details of the parameters used. 
The optimized concentration of HAM/ Fibrin construct is used in further studies 
involving the feasibility of the construct in maintaining and supporting chondrocytes 
proliferation and maintenance of matrix production. Incorporation fibrin in this scaffold 
is as an integral part to HAM in order to hold the two materials together, thus forming 
what we called the HAM/ Fibrin scaffold. 
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4.2 Methods 
Primary cells from adult bovine joints as explained in Chapter 3 were obtained and 
used in optimizing the HAM/ Fibrin constructs. 
4.2.1 Different concentrations of HAM to Fibrin ratio 
After successful cell digestion, cell count and cell viability check (~90% alive), the 
chondrocytes were suspended in 10 ml of culture medium. The different concentration 
of HAM and fibrin were prepared as mentioned in Table 3.3. First, the pre-weighted 
sterilized HAM was mixed with fibrinogen in a cell suspension in accordance to Table 
3.3. Then, the HAM-cell suspension was injected simultaneously with thrombin 
supplemented with CaCl2 into a custom-made 316L stainless steel mould using a multi-
channel pipette as previously described in section 3.6.  
4.2.2 Incubation Time 
  The duration of incubation time to set the HAM/ Fibrin scaffold was evaluated. 
The incubation time was at 30, 45 and 60 mins in 5% CO2 and 37°C. 
4.2.3 Cell Concentration 
The amount of cells used in the optimization of HAM/ Fibrin scaffold was also 
evaluated. The numbers of cells were as stated in Table 3.3. 
4.3 Results 
All of the scaffolds had cells incorporated into them as part of the process, as direct 
injection moulding method is being used instead of the surface seeding method. As a 
result, we can directly monitor the physical appearance of the scaffold as shown in 
Table 4.1. 
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Table 4.1: Result of optimization of HAM/ Fibrin scaffold. 
Cell number 
(millions/ ml) 
HAM : Fibrin 
(v/v) 
Setting Time 
(minute) 
Observations 
1 
0.5:1 
30 Turbid, fail to polymerized 
3 45 Turbid, fail to polymerized 
5 60 Turbid, fail to polymerized 
1 
1:1 
30 Clear & complete polymerization 
3 45 Clear & complete polymerization 
5 60 Clear & complete polymerization 
 1 
1:0.5 
30 
Turbid, polymerization occurs on 
half outer diameter 
3 45 
Turbid, polymerization occurs on 
half outer diameter 
5 60 
Turbid, polymerization occurs on 
half outer diameter 
 
The optimization protocol resulted in an optimized HAM/ Fibrin scaffold with a final 
concentration of 50 mg/ml (1:1 HAM to fibrin ratio) with a thrombin concentration of 
2.5 U/ml, CaCl2 at 20 mM, and ~5 million/ml chondrocytes set within 30 minutes time. 
4.4 Discussion 
 A tissue engineering scaffold has the main function to provide adequate cellular 
attachment and adhesion. It should allow cell migration, proliferation, nutrient and 
waste exchange whilst providing space for tissue development. The stability of the 
shape is also an important factor whereby it is necessary for the scaffold to provide 
sufficient time for cells to produce their specific matrix while the scaffold slowly 
degrades as the occupying cells replace the scaffold.  
Optimizations of the constructs are to assess the best concentration of HAM to fibrin 
ratio. This procedure is vital before we proceed with other assessments to ensure that 
the constructs are at its optimum condition; cell to scaffold ratio, attachment and its 
physical appearance.  
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Cross-linking HAM with fibrin as stated in Table 4.1 has varied in results. However, 
there are similarities to all the three different cell number in the same 1:1 (v/v) HAM to 
fibrin ratio. In all of these three conditions; 1, 3 and 5 million in a final concentration of 
cell number in the construct, it appears to show complete polymerization with no 
change in size and shape after being released from the custom-made mould. The 
constructs appear to be clear with the shape according to the mold (D: 5 mm, H: 5 mm). 
As for the other two HAM to fibrin concentration; the results showed negative outcome 
as one fails to achieve complete polymerization [0.5:1(v/v)]  and other showed partial 
polymerization [1:0.5 (v/v)] after suggested incubation time and after being released 
from the mould.  
Variation of the fibrin gel appearance has been mentioned in many studies 
(Kjaergard & Weis-Fogh, 1994; Sidelmann, Gram, Jespersen, & Kluft, 2000). The gels 
with a concentration of 0.5: 1 of Ham to fibrin ratio (v/v) appeared to be turbid and did 
not polymerize completely and almost completely dissolved when being released from 
the mould following sufficient incubation time. This result was reported as the 
constructs has large fiber diameter and large pore size in the fibrin clot formation or the 
construct formation in this case.  
In contrary, the gels with a concentration of 1:0.5 of HAM to fibrin ratio also appear 
to be turbid and had partial polymerization at the outer diameter of the constructs. 
Releasing the constructs from the mould resulted in partial gelation of the construct with 
some contraction as the middle whereby it appears to be hollow and this cannot be 
accepted to proceed as an optimum concentration of HAM to fibrin ratio for further 
investigation.  
It is known that the variation of fibrinogen concentration may affect the gel 
appearance and stability (Kjaergard & Weis-Fogh, 1994; Sidelmann et al., 2000). At a 
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low concentration of fibrinogen, the fibrin may appear to be turbid which attributed to 
the large fiber diameter within the fiber mesh network. And in contrary, it has also been 
reported that increased fibrinogen concentration resulted in finer and thinner fiber 
network thus more rigid and appear clear and less turbid. In our case, however, the 
increased of fibrinogen concentration has no effect on the gel appearance as the 
incorporation of HAM should somehow play a role in the lagging the polymerization of 
the fibrin.  
From this study, we found the best way to optimize HAM to fibrin concentration in 
order to proceed with other tests to determine the feasibility of this new cell-scaffold 
construct for cartilage tissue engineering application. It is evident that the best 
concentration is at 1:1 (v/v) ratio of HAM to fibrin concentration with 30 minutes 
incubation time. The highest amount of cells was chosen as reports of higher viable 
cells seeded supports matrix production (Provin, Takano, Sakai, Fujii, & Shirakashi, 
2008; Solchaga et al., 2006). As stated earlier, the optimized concentration will be the 
basis of the HAM/ Fibrin construct for all of the tests and investigations.  
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CHAPTER 5: STUDY 2 - FEASIBILITY OF THE HAM/ FIBRINCONSTRUCTS 
IN CARTILAGE TISSUE ENGINEERING APPLICATION ON CELLULARITY 
AND EXTRACELLULAR MATRIX PRODUCTION 
5.1 Introduction 
In order to evaluate the scaffold properties, the feasibility of the scaffold for 
chondrocytes growth and production of ECM, an in vitro study was conducted. We 
managed to fabricate and optimized the HAM/ Fibrin scaffold in the first part of the 
study. This chapter is a continuation of the previous chapter explaining the biochemical 
and histological evaluation of the optimized HAM/ Fibrin construct covering the aspect 
of evaluating the rate of ECM production, cell proliferation and looking into the cells 
morphology and histological evaluation. This chapter will generally describe the 
experimental study that has been done to access the feasibility of this newly fabricated 
construct with the influence of chondrocytes. As previously described, this study will 
not include nor discuss the biomechanical properties of the scaffold. 
5.2 DNA Production 
Upon constructing the HAM/ Fibrin scaffold seeded with chondrocytes, we managed 
to evaluate the total DNA content of the constructs within a period of 4 weeks according 
to the protocol mentioned in section 3.8. The constructs were subjected under 
physiological condition and were under static culture. Throughout the culture, the 
scaffolds seeded with chondrocytes were maintained at 37°C and in a 5% controlled 
humidity at all times. 
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5.2.1 Result 
 
Figure 5.1: Total DNA over 4 weeks of culturing period. The data shown are as 
mean±standard error mean (SEM), where n=12, **represents p<0.01, and 
*represents p<0.05. 
 
The influence of chondrocytes within the HAM/ Fibrin scaffold on the DNA content 
is presented as in Figure 5.1. Following protocol under section 3.8, specimens were 
immediately removed and undergone Papainase digestion and were subjected to DNA 
measurement. The DNA content within the 4 weeks culturing period increased 
substantially from week 1 to week 4. Although there was no significant difference over 
control in each week, there was a slight difference in HAM/ Fibrin DNA content 
throughout the entire experiment. 
5.3 GAG Production 
Under the 3D influences, chondrocytes-seeded scaffolds resulted in GAG synthesis 
and retention within the ECM. Another study that was also performed to evaluate the 
feasibility of the scaffold in in vitro setting was the GAG production. The constructs 
were subjected to the processed as described in section 3.8. Throughout the culture 
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period, the scaffolds seeded with chondrocytes were also maintained at 37°C and 5% 
controlled humidity at all times. 
5.3.1 Result 
 
Figure 5.2: Evaluation of GAG content production. Data represent mean and 
standard of mean, where n=12, ** represents p<0.01, and * represents p<0.05 when 
compared between the 2 constructs across 4 different days of culture. 
 
The influence of chondrocytes within the HAM/ Fibrin scaffold on the GAG content 
is presented as in Figure 5.2. Upon timely manner, the constructs were subjected to 
Papainase digestion following protocol as described in section 3.8 for GAG 
measurement. The total GAG content increased significantly as compared to control 
between weeks. Although initially, at the beginning of the study, the GAG content was 
p<0.05 as compared to control it increased significantly in the following week with the 
significance of p<0.01 and were 3 folds higher in HAM/ Fibrin constructs as compared 
to initial week 1. At the end of week 4, GAG content in HAM/ Fibrin constructs were 
30% higher than control. 
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5.4 Confocal Microscopy 
Assessing the viability of cells inside 3D scaffolds is an important parameter in tissue 
engineering study. It is used to evaluate the survival of the cell in in vitro culture. In this 
study, the cell viability was performed on the construct with the aid of a confocal 
microscope with the Live/Dead assay. The principle behind the Live/Dead assay is the 
dimeric-dyes used; Calcein-AM and Ethidium Homodimer. Ca-AM is enzymatically 
hydrolyzed into Calcein in living cells, turning it green upon contact. Meanwhile, 
Ethidium Homodimer will only be able to stain the nuclei red by entering compromised 
cell membranes. The scaffold seeded cells were subjected to a dimeric-dye as described 
in section 3.8. Throughout the culture period, the scaffolds seeded with chondrocytes 
were maintained at 37°C and 5% controlled humidity at all times and were subjected to 
the Live/Dead assay on day 7 and 28 of culturing period. 
5.4.1 Result 
At the end of week 1 of culture, both HAM/ Fibrin scaffold as shown in Figure 5.3 
(a) and control in Figure 5.3 (c) were subjected to the Live/ Dead assay in order to 
evaluate the cellular viability. It is notable that both groups displayed homogenous cell 
dispersion throughout the scaffold. The initial cell dispersion appears to be sparse due to 
the initial cell seeding of approximately five million cells. Both groups displays high 
cell survival with no red staining to indicate cell death. At the end of the culturing 
period, at week 4, both groups were again subjected to the same protocol and results are 
as shown in Figure 5.3 (b) and (d). HAM/ Fibrin scaffold displayed to have higher cell 
survival as compared to the control group. Fibrin scaffold has been well recognized to 
support cell survival in vitro and the macroscopic observation clearly supports this 
(Hunter, Mouw, & Levenston, 2004; Munirah, Samsudin, Aminuddin, & Ruszymah, 
2010).  
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Figure 5.3: The morphology and viability of the HAM/ Fibrin construct 
cultured for (a) 7 and (b) 28 days. The morphology and viability of the fibrin 
construct cultured for (c) 7 and (d) 28 days.  
Although both groups were negative of Ethidium Homodimer stain identifying the 
dead cells, HAM/ Fibrin scaffold appears to be fully occupied by the chondrocytes as 
evidently the scaffold is densely stained with the green dye of Calcein-AM as shown in 
Figure 5.3 (b). The results concur to be relatively comparable to the previous findings in 
GAG and DNA content productions presented in section 5.2.1 and 5.3.1. 
5.5 FESEM 
FESEM is an excellent method to determine the biocompatibility of materials in 
Tissue Engineering applications. It has been widely utilized in assessing the surface 
morphology and the architecture of 3D scaffolds. By using FESEM micrograph, 
observations of the interface between cells and the materials, the homogeneity of the 
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surface layer and the cellular attachments and adhesion behavior can be done. Both 
groups of the scaffold was subjected to FESEM processing as mentioned in section 
3.10. 
5.5.1 Result 
The FESEM images of the constructs at day 1 are as shown in HAM/ Fibrin 
construct appeared to be porous in nature as displayed in Figure 5.4 (a) and (b) 
respectively. The surface morphology is evidently different as compared to the control 
group fibrin as shown in Figure 5.4 (c) and (d). Fibrin scaffolds have been well 
documented to have fiber-oriented surface and morphology (Collet et al., 2000; des 
Rieux et al., 2009; Noailly, Van Oosterwyck, Wilson, Quinn, & Ito, 2008). This surface 
morphology appear to be the same for all scaffold made from fibrin (Bensaı̈d et al., 
2003; Bhardwaj et al., 2011; Blombäck & Bark, 2004; Eyrich et al., 2007; Garcia-
Fuentes, Meinel, Hilbe, Meinel, & Merkle, 2009; Hokugo, Takamoto, & Tabata, 2006).  
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Figure 5.4: FESEM image of HAM/ Fibrin construct at Day 1 of culture (a) 50 
µm, (b) 15 µm and Fibrin scaffold at Day 1 of culture (c) 50 µm, (d) 15 µm.  
 
The porous surface and morphology of HAM/ Fibrin scaffold in Figure 5.5 (a) 
resulted in good chondrocyte attachment and adhesion as observed in Figure 5.5 (c). 
The control group with fiber surface and morphology in Figure 5.5 (b) also displayed 
good chondrocyte attachment as indicated in Figure 5.5 (d). The matrix production was 
evident as there are signs of cell-cell, cell-ECM adhesion and cytoskeletal filaments. 
Both groups maintained apparent chondrocyte phenotype as the cells appear to be round 
in shape as evident in Figure 5.5 (c) and (d). The chondrocytes appear to be dissipating 
homogenously throughout the scaffold in both groups.  
a 
d c 
b 
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Figure 5.5: FESEM micrographs of (a) HAM/ construct at day 7 of culture. (b) 
Fibrin construct at day 7 of culture. (c) HAM/ Fibrin construct at Day 28 of 
culture. (d) Fibrin construct at day 28 of culture. The magnified feature of each 
micrograph (blue accent) is presented as an inset image (olive green). 
 
5.6 Histology 
Histological and histochemical protocols are an important tool in evaluating tissue 
morphology. The most basic histological staining for general assessment of cell, tissue 
morphology and distribution is Hematoxylin and Eosin (H&E) staining. Hematoxylin 
stains the cells nuclei purple and cartilage ECM pinkish in color. The H&E staining was 
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performed in accordance with the protocol mentioned in section 3.9. The constructs 
were assessed at day 7 and day 28. 
Following the basic Hematoxylin and Eosin staining, Safranin-O staining was 
performed in order to further assess the PG contents of the construct. As a cationic dye, 
Safranin-O stains PG as well as glycosaminoglycan. Safranin-O is a proteoglycans 
indicator as the staining intensity is directly proportional to the PG content. The 
Safranin-O staining was done at day 7, 14 and 28 according to the protocol as in section 
3.9.  
5.6.1 Result 
The H&E staining of the HAM/ Fibrin and Fibrin constructs are as shown in Figure 
5.6 (a) and (c), respectively. The initial staining was at week 1 of culture. Both groups 
of HAM/ Fibrin and Fibrin appear to be mildly stained with H&E indicating lower 
cellular component within the construct. During the final week, at day 28, the staining 
appeared to be deeper in color and in HAM/ Fibrin construct (Fig. 5.6(b)), the stain 
became apparent and more distinct as compared to the control group (Fig. 5.6(d)) which 
appears to be less apparent in H&E stains. These results are parallel to the findings in 
section 5.2.1 and 5.3.1. 
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Figure 5.6: Hematoxylin & Eosin staining on HAM/ Fibrin construct at (a) Day 
7 and (b) Day 28.  Hematoxylin & Eosin staining on Fibrin construct at (c) Day 7 
and (d) Day 28. 
The staining evidence of Safranin-O staining for both groups is as shown in Figure 
5.7 - Figure 5.9. During the initial week, the staining appears to be rather weak with a 
slight appearance of pinkish stains in HAM/ Fibrin constructs as well as control group 
as indicated in Figure 5.7(b) and 5.7(a) respectively. The cells appear to be sparsely 
located and low in number. At day 14, the staining appears to show a slight increase in 
cell number in both groups with HAM/ Fibrin construct (Fig. 5.8(b)) showing no 
significance to control (Fig. 5.8(a)). In the final week, the staining appears to have 
streaks of mild red staining across the specimen indicating cartilage matrix production 
  
82 
 
as shown in the respective Figure 5.9 (a) and (b). Both groups displayed this mild 
staining and results can concur to the results from section 5.2 - 5.5 accordingly. The 
indication of bluish stain represents the accumulation of proteoglycan contents in that 
area, being deeper in color representing higher content in PG. This finding further 
supports the GAG content production in the previous result as mentioned in section 
5.3.1. The control group was indicating results as reported previously by other studies 
(Scotti et al., 2010; van Susante et al., 1999). 
 
Figure 5.7: Safranin-O staining at Day 7 of (a) Fibrin and (b) HAM/ Fibrin 
constructs. 
 
 
Figure 5.8: Safranin-O staining at Day 14 of (a) Fibrin and (b) HAM/ Fibrin 
constructs. 
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Figure 5.9: Safranin-O staining at Day 28 of (a) Fibrin and (b) HAM/ Fibrin 
constructs. 
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CHAPTER 6: DISCUSSION 
6.1 Introduction 
This chapter draws together all the work that has been done in the previous chapters. 
This chapter discusses in depth the choice of sustainable biomaterials involved, 
fabrication techniques, and methodologies. Furthermore, the mechanism that is 
responsible for the modification of the architecture is discussed. This chapter also 
discusses how HAM is responsible for the up-regulation of cell viability and the key 
findings of the entire study. We first touch on the fabrication of the scaffold, and on 
how optimizing the scaffold plays an important role in order to continue with assessing 
the feasibility of the scaffold for cartilage tissue engineering applications. Next, we will 
be discussing the investigation of the feasibility of an optimized scaffold to support 
cartilage cell proliferation.  
Furthermore, we discussed the results and discussions in depth to draw an 
understanding of the findings in this study in addition to cartilage tissue engineering 
scaffold/ field.  
6.2 Suitability of Biomaterials 
The present study utilized HAM and fibrin for three dimension scaffold fabrication 
both known to be sustainable biomaterials. HAM has been clinically utilized in 
numerous clinical studies (Branski et al., 2008; Leon-Villapalos et al., 2008; M. Li et 
al., 2006; Sheridan & Moreno, 2001). HAM availability is virtually limitless with 4 
births recorded per second worldwide. The ECM components of HAM which includes 
collagens, fibronectin, laminin, proteoglycans and hyaluronan are almost as similar to 
the ECM that is found in the native cartilage. 
HAM possesses several clinical advantages as a biomaterial. Its properties of 
bacteriostatic, anti-microbial, anti-fibrosis, anti-angiogenic, anti-inflammatory and also 
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the ability to inhibit scarring hence enhance wound healing in vivo. None of these 
characteristics are shared by any other biomaterials be it natural of origin or synthetic. It 
has been documented that HAM poses almost no immunogenicity although the 
transplantation risk is always of concern (Branski et al., 2008; Bujang-Safawi et al., 
2010; Hasegawa et al., 2004). Through strict screening of HAM donor, this biomaterial 
is an excellent candidate for cartilage tissue engineering application. The challenge in 
culturing chondrocytes using HAM for tissue engineering applications is in culturing it 
in a 3D setting. It has been well established that monolayer culture of chondrocyte 
resulted in loss of chondrocytic phenotype (Benya & Shaffer, 1982). Hence the need to 
turn HAM into a 3D scaffold would be more suitable in reaping the benefits that it has 
for tissue engineering applications. The other challenge in utilizing HAM in a 3D form 
or setting is that it does not set itself after freeze-dried processes. The need for an 
adhesive material to set and crosslink it together is inevitable. Fibrin has long been 
studied and applied in tissue engineering applications. Fibrin gel which is a naturally 
occurring biodegradable biomaterial has high affinity to various biological surfaces. 
Being naturally occurring physiological scaffold in our body, it supports angiogenesis 
and tissue repair. Fibrin naturally contains sites for cellular binding and adhesion and 
has been shown to have excellent cell seeding affinity and good tissue development. 
The most appealing factor for using fibrin as the hybrid polymer for this study is the fact 
that fibrin gels can be autologously derived from patients’ own blood, eliminating the 
potential risk of immuno-rejection. Scaffolds made from natural biomaterials have 
advantages such as innate biological ligands that helps induce cell recognition to 
promote cellular remodeling (Munirah et al., 2010; Scotti et al., 2010; Wozniak, 2003). 
6.3 Optimization of HAM/ Fibrin Scaffold 
In assessing this newly fabricated scaffold, optimization ensures the best composition 
in maintaining chondrocyte phenotype, maintenance and production of cartilage matrix 
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components. Optimization is crucial to evaluate the scaffold capacity to retain its shape 
and form without sudden failure whilst retaining the cells inside. The optimization study 
was essential before other studies could proceed. There are many methods that can be 
utilized in fabricating a 3D scaffold as described in detail in section 2.7.3.4. The method 
that was used in fabricating this 3D HAM/ Fibrin construct is via in situ crosslinking 
through direct injection moulding method. The absence of high heat influx, which is a 
common mode of 3D scaffold fabrications, eliminates the need of time-consuming 
scaffold preparation. The results from optimizing the scaffold fabrication are beneficial 
to be used in clinical applications. In terms of practicality, the HAM/ Fibrin construct 
would be a great advantage for the non-invasive procedure as it can be directly injected 
into various shapes and spaces within the suggested time period. The HAM/ Fibrin 
construct can also be assessed optically based on the results in section 0.  
6.4 Cell Seeding Density 
It is well known that fibrin set after a certain period of time into a solid form. Due to 
this, cells are incorporated into the HAM/ Fibrin scaffold before solidification occurs. 
The need for higher cell density as previously reported resulted in the synthesis of 
functional matrix (Mauck, Wang, Oswald, Ateshian, & Hung, 2003). This present study 
also used high cell density at 5 x 10
6 
cells/ ml and was proven to be the optimized 
concentration that follows in all tests evaluated. The cell density of 5 X 10
6
 cells/ ml 
was sufficient to access characterization and analysis of the 3D scaffold as reported in 
Chapter 5.  
6.5 Feasibility of HAM/ Fibrin Scaffold for Cartilage Tissue Engineering 
Application  
In this present work, the feasibility of the HAM/ Fibrin scaffold can be measured and 
assessed by analyzing the total DNA and GAG content production. The total DNA 
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content production assessment can be related directly to the cell density inside the 
constructs. Cell density can be calculated with the assumption of DNA/ cell to be at 7.7 
pg as previously reported (Y. J. Kim, Sah, Doong, & Grodzinsky, 1988). The result 
shown in section 5.2.1 represents the total DNA content production. Throughout the 
whole study, HAM/ Fibrin scaffold appears to have slight differences in DNA content 
compared to the control group. The presence of fibronectin, laminin, proteoglycans and 
hyaluronan that was reported in HAM could contribute to this result. 
The total GAG content production correlates directly to the ECM production by 
chondrocytes. The result shown in section 5.3.1 represents the total GAG content 
production. This result represents the feasibility of the constructs in supporting and 
maintaining chondrocyte metabolism. Throughout the whole study, HAM/ Fibrin 
evidently resulted with higher GAG production. The presence of HAM in the construct 
may be contributing to this result by having similar ECM to the native cartilage in 
particular proteoglycans and hyaluronan. This suggests that GAG production is higher 
in HAM/ Fibrin scaffold although it is apparent that the amount of cells was not much 
different to the control group as in section 5.2.1. HAM/ Fibrin scaffold could encourage 
the higher GAG content production by inducing ECM production. The 
microenvironment within the scaffold must be feasible for the chondrocytes to excrete 
higher GAG production as compared to control.   
The Live/Dead assay further supports the previous results of DNA and GAG content 
production. Both groups were able to retain viable cells. The cell viability was apparent 
at day 7. Both groups showed homogenous cell dispersion throughout the scaffold. This 
is due to the incorporation of cells together with fibrin before solidification as described 
in section 3.6. The chondrocytes were dominating and occupying the HAM/ scaffold by 
day 28. This result further supports the findings in section 5.2.1 and 5.3.1, namely the 
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DNA and GAG content production. The presence of HAM in the scaffold may have 
contributed to the high cell survival. The components that can be found in HAM have 
certainly had effects on this as well. As compared to fibrin, if HAM has no significant 
effect at all, then the results of both groups should be the same. It has been well 
documented that HAM supports cellular survival (Gruss & Jirsch, 1978); (J. Kim et al., 
2000). It is apparent that the presence of HAM in HAM/ Fibrin scaffold enhances the 
survival of cells in vitro and induces the ECM production.  
The FESEM images as shown in section 5.5, represents HAM/ Fibrin and fibrin 
scaffold. The morphology and architecture of the scaffold can be observed in detail. 
HAM/ Fibrin scaffold was observed displaying porous structure and surface 
morphology, a very distinct feature from a fibrin hybrid scaffold. Previous study that 
involves fibrin, have always been documented to display fiber orientation when it 
comes to its surface morphology and architecture. This result is due to the presence of 
HAM that has totally changed the normal display of fibrin based scaffold. We do not 
know exactly how this happened, but by incorporating HAM, the scaffold appears to be 
more porous. This is a good characteristic for a scaffold meant for cell attachment and 
adhesion molecules to cling onto. This may explain the higher GAG content production 
and cell survival as indicated previously in section 5.3.1.  
The FESEM images at day 28 also showed both groups displayed good cell 
attachment and adhesion. The cytoskeletal filaments were apparent in both groups 
indicating the presence of cell-to-cell and cell-to-matrix communication. The cells 
appear to be round in shape, indicating that chondrocytic phenotype was attained in both 
micro-environments. This showed that either fiber orientation or porous surface were 
able to retain chondrocytic phenotype for the chondrocytes. 
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Histological staining was also viable for both groups. Both H&E and Safranin-O 
staining further support the findings on section 5.2 to section 5.5. This indicates that 
HAM/ Fibrin scaffold was feasible to support chondrocyte survival and metabolism. It 
was apparent that the histological evidence indicates the cellular proliferation and ECM 
production by the colors it displayed. 
Hyaluronic acid (HA) is widely used in treating OA due to its chondroprotective 
effects. AC is known to actively produce reactive oxygen and nitrogen species capable 
of causing chondrocyte dysfunction and apoptosis (Grishko et al., 2009; Jahn, Baynes, 
& Spiteller, 1999; Rahman & MacNee, 2002; Ray, Huang, & Tsuji, 2012). It has been 
documented that Hyaluronic Acid inhibits reactive oxygen species and nitrogen species 
(Cirillo et al., 2015; Soltes et al., 2006). We hypothesize that the HA in the HAM/ 
Fibrin scaffold contributed to the survival of the chondrocytes as reported in Chapter 5 
as there  was increased proliferation shown by the DNA results.  
6.6 The Advantages of 3D HAM/ Fibrin Scaffold 
Fibrin is a well-documented biodegradable and resorbable natural biomaterial 
(Bensaı̈d et al., 2003; des Rieux et al., 2009; Eyrich et al., 2007; Janmey, Winer, & 
Weisel, 2009b; Shaikh et al., 2008), however by supplementing the medium with ε-
Amino Caproic Acid (εACA), we were able to controlled the fibrinolysis of the scaffold 
hence aiding the chondrocytes proliferation (Adelman, Rizk, & Hanners, 1988; Collet et 
al., 2000; Kupcsik, Alini, & Stoddart, 2008; Ries & Zenker, 2003; Soter, Austen, & 
Gigli, 1975). The presence of HAM in the scaffold resulted with higher GAG 
production was probably due to better ECM production with better cell-ECM 
interactions. The presence of known integrin in HAM could also be contributing to this 
hence higher proliferation inside the scaffold as compared to the control group. 
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As fibrin initiates cellular attachment, as seen in both groups during the first week as 
can be seen from the total GAG and DNA results, the HAM/ Fibrin scaffold definitely 
resulted in higher GAG and DNA content towards the third and fourth week. Similarly, 
collagen in HAM has been known to help in promoting and enhancing GAG synthesis, 
and maintenance of chondrocyte phenotype (Díaz-Prado et al., 2010) 
The HAM/ Fibrin constructs displayed a different surface morphology than the 
control and any other fibrin crosslink constructs. As multiple studies done previously, 
none reported in these changes (Bensaı̈d et al., 2003; Bhardwaj et al., 2011; Blombäck 
& Bark, 2004; des Rieux et al., 2009; Eyrich et al., 2007; Harold A, 2004; Janmey, 
Winer, & Weisel, 2009a; Sha'ban, Kim, Idrus, & Khang, 2008). The fiber orientation of 
the fibrin matrices in the HAM/ Fibrin scaffold were transformed to porous-like 
architecture, which is favored in scaffold fabrication for better cell attachment.   
It is known that HA enhanced cell attachment, proliferation and differentiation of 
chondrocytes in cartilage tissue engineering applications. The HA presence in HAM 
was observed to enhance attachment of chondrocytes with significant GAGs and DNA 
content production. The presence of HA has been reported to induce cartilage tissue 
engineering in terms of tissue morphological characteristic (Yoo, Lee, Yoon, & Park, 
2005). This could be the reason for the change in the morphological structure of HAM/ 
Fibrin that differs from other fibrin-based scaffold. 
6.7 The Effect of HAM to Chondrocyte Behavior 
It has been reported that IL-1 cytokines have clinical effects on the cartilage erosion 
(Westacott & Sharif, 1996). HAM is known to have anti-IL-1 cytokines that could 
possibly reverse or halt the progress of cartilage degeneration (BrunoFautrel, 2012). 
Moreover, another study has also reported that the presence of HAM suppresses the 
activity of IL-1 cytokines in cell culture (Solomon et al., 2001). These reports are in line 
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with the results that have been documented in section 5.2.1 - 5.4.1. Cell viability was 
apparent in all these tests which are parallel to previous studies. This scaffold might be 
suitable for cartilage tissue engineering applications considering the multiple properties 
it possesses that would be an advantage if it is able to advance into clinical trials.  
6.8 Possible contribution in a clinical setting 
In a clinical case scenario whereby if the patient has a full thickness defect as shown 
in Error! Reference source not found., the subchondral bone is exposed and the 
injectable HAM/ Fibrin scaffold could plug the area/exposed site. The exposed 
underlying subchondral bone would allow blood to bind/ interact with the scaffold due 
to the presence of fibrin in the scaffold. Even though there are concerns of fibrous 
formation at the “border” of the scaffold subchondral bone; the interconnection between 
the newly formed scaffold and the native tissue site, reports of HAM within the scaffold 
poses a great advantage of an anti-inflammatory, anti-angiogenic, and anti-scarring 
agent could possibly halt the fibrous tissue formation at the site of scaffold-subchondral 
bone margin/ periphery/ boundary. This could be a possible injectable scaffold that 
clinicians could use in clinical settings for smaller defects in the articular cartilage 
region. Although the biomechanics of the scaffold has not been assessed in this study, 
the use of this scaffold in a clinical setting for defects of less than 1 cm
2 
should not 
induce further damage to the surrounding tissues. It is more likely to have successful 
cell-cell integration to the adjacent tissue/ neighboring tissue due to the presence of 
HAM and fibrin with almost similar ECM in that of native cartilage. 
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CHAPTER 7: CONCLUSION 
7.1 Introduction 
This chapter concludes the work that was discussed in the previous chapters and 
suggests some possible direction of future work.  
7.2 Summary of Key Findings 
Generally, we can conclude that this study has: 
i. successfully fabricated a 3D HAM/ Fibrin scaffold optimized at a 
concentration of 1:1 (v/v) ratio with 5 million cells/ml set within 30 
minutes; 
ii. demonstrated that the 3D HAM/ Fibrin scaffold supports chondrocyte 
proliferation and cartilage matrix production; and 
iii. demonstrated that the 3D HAM/ Fibrin scaffold may serve as a potential 
cell delivery vehicle and a structural basis for in vitro tissue engineered 
articular cartilage. 
7.3 Knowledge Contribution from This Work 
i. Development of HAM extract from two dimensional Human Amniotic 
Membrane. 
ii. Development of 3D HAM/ Fibrin as a cell delivery vehicle in 
simultaneous injectable form for potential use in minimally invasive 
surgical procedure. 
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7.4 Future Work and Recommendations 
Although the studies that were reported in this dissertation has proven a few new 
details on the HAM/ Fibrin scaffold, further studies can be carried out to better 
understand this newly developed scaffold for Tissue Engineering applications. 
7.4.1 Biomechanical Property Evaluation 
As tissue-engineered cartilage is meant to be utilized in a load bearing area, a 
biomechanical study needs to be done in order to verify the biomechanical properties of 
this HAM/ Fibrin scaffold. The study may include static and dynamic biomechanical 
testing in a bioreactor to determine the influence of mechanical load on cell 
proliferation, ECM production and maintenance of this novel scaffold. 
7.4.2 Measurement of Other Biochemical Parameters 
This study has shown that the 3D HAM/ Fibrin scaffold supports matrix production, 
based on the analysis of DNA and GAG content production. Nevertheless, delivering 
similar objectives to further study other biochemical parameters, different tests can be 
conducted to verify the presence of collagen type II production and phenotypic 
expression via gene expression. The tests may include the SOX 9, Aggrecans, and 
COMP test, in order to further confirm the role of HAM/ Fibrin scaffold in cartilage 
tissue engineering application. 
7.4.3 Animal/ In vivo testing 
It has become apparent that following a successful in vitro culture of cartilage 
engineered tissue, an in vivo test or animal test/ transplantation should be done to further 
evaluate the effects and reaction of the HAM/ Fibrin scaffold in a native environment. 
Moreover, in vivo tests could also investigate the theory of whether there is a possibility 
of a good HAM/ Fibrin to subchondral bone fusion and whether there are a good ECM 
attachment and coherent chondrocyte proliferation to induce better cartilage repair.  
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